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ABSTRACT 
Background. Anxiety-related problems are one of the most common yet poorly understood 
behavioural abnormalities among domestic dog (Canis familiaris). Common anxiety traits, 
such as shyness, noise phobia, generalized fear and separation anxiety may severely affect not 
only dog’s own quality of life and routine but also people and other dogs around, frequently 
resulting in abandoning, sheltering or euthanasia of the dog. Although studies have 
demonstrated that genetics, environment, and their interaction contribute to anxiety 
pathogenesis, better knowledge is highly needed to improve diagnostics and treatment of 
these detrimental conditions. At the same time, the study of canine anxiety may inform our 
own anxieties. Clinical, ethological and pharmacological studies suggest that the underlying 
biochemical networks may be shared in dogs and humans. Canine purebreeding has resulted 
in a unique genetic system, which may help us to identify molecular mechanisms across 
species. However, relevant phenotyping approaches and biomarkers are needed for proper 
establishment of study cohorts.  
Objective. This pilot metabolomics study is a part of larger ongoing anxiety program in prof. 
Lohi’s laboratory, which aims to unravel the genetic and environmental correlates of canine 
anxiety as a natural model of human anxiety. The goal of the study was to investigate possible 
differences between metabolite profiles of anxious and non-anxious dogs. Possible identified 
anxiety-related metabolites could refer to underlying biological problem and serve as 
candidate biomarkers for further validation studies.  
Material and methods. Ten fearful and ten non-fearful dogs were selected to this study and a 
liquid chromatography combined with mass spectrometry (LC-MS)-based non-targeted 
metabolomics analysis was performed from whole blood samples to detect the whole 
metabolite profiles of the test groups. Samples were prepared according to protocols used in 
similar human studies, and the metabolic features detected by UHPLC-qTOF-MS system 
were identified by matching the features to online chemical library databases. Statistical 
analysis of the detected metabolites between case and control groups was performed by Mass 
Profiler Professional software (MPP 2.2, Agilent Technologies).  
Results. We detected altogether 6 932 entities during the study, of which 165 were evaluated 
as statistically significant between the test groups. 14 significantly altered metabolites in the 
fearful dogs were identifiable in putative level, including hypoxanthine, indoxylsulfuric acid 
and several phospholipids. These molecules are known to be involved in oxidative stress, 
inflammation, tryptophan metabolism, and lipid metabolism. 
Conclusions. Although a larger replication study with more methodological optimization is 
needed, this pilot study demonstrates that the non-targeted metabolomics approach is an 
effective method to investigate biological backgrounds of behavioural abnormalities also in 
dogs. The identified altered metabolites appear relevant to anxiety disorders and have been 
found affected also in other models.   
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1 INTRODUCTION  
An increasing number of dogs are suffering from anxiety-related conditions, such as shyness, 
noise phobias, generalized fear and separation anxiety (Pineda et al., 2014). Shyness against 
strangers, other dogs or novel situations and fear of loud noises are particularly common 
problems across breeds (Tiira and Lohi, 2014). Fear is expressed in several ways in dogs and 
responses vary according to the source of stimuli (Hydbring-Sandberg et al., 2004). Most 
common reactions to social fear include avoidance, escape, immobility or aggressive 
behaviour. Exposure to loud noises, such as gunshots, fireworks or thunders, may cause 
panting, tremble, cower, escape or hiding (Dale et al., 2010). In the worst cases, the fear 
reaction may evolve beyond control, leading to a complete panic and developing into a 
generalized fear, which may weaken dog’s quality of life, and complicate the everyday life of 
its owner and other people or dogs around it. Moreover, regrettably many dogs are 
abandoned, sheltered, or even euthanized because these highly destructive and severe 
symptoms of anxieties, but fortunately some canine anxieties are treated with positive 
outcomes with anxiolytes, behavioural therapy, and the combination of these nowadays 
(Gruen and Sherman, 2008).    
High heritability estimates suggest a genetic contribution to shyness and noise phobia in dogs 
(Tiira and Lohi, 2014). However, not only genes but also environmental factors and their 
interactions affect to the development of anxiety-related conditions in dogs. These 
environmental factors include, for example, negative or even traumatic experiences of people 
or loud noises, and poor socialization during puppyhood (Foyer et al., 2013). Furthermore, 
Foyer et al. (2013) showed that even the litter size and the season of birth may influence the 
development of dog’s behaviour and capability to cope in stressful situations. Moreover, 
human, canine and rodent studies implicate that also maternal care, prenatal stress, and 
nutrition may play a role in the development of anxiety-like behaviour (Bennett et al., 2002; 
Bravo et al., 2014; Hennebelle et al., 2014; Liu et al., 2013; Meaney and Szyf, 2005; 
Pierantoni et al., 2011).  
Human anxiety-related conditions include post-traumatic stress disorder, panic disorder, 
obsessive-compulsive disorder, generalized anxiety disorder and social phobia (Gross and 
Hen, 2004). However, genetic studies have been challenging due to clinical and genetic 
heterogeneity of the anxieties, and therefore, research utilizing information available from 
dogs may help us to understand the molecular backgrounds of anxiety across species. 
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Clinical, ethological and pharmacological studies suggest that the underlying biochemical 
mechanisms may be shared in dogs and humans (Overall, 2000).  Dogs share the same 
environment with humans and are often treated with human anxiolytes with a positive 
outcome. As a large animal, dog is physiologically closer to human and diseases tend to 
develop more similarly when compared to rodents. Aggressive breeding has led to the 
existence of more than 350 distinct breeds specifically developed for different tasks, such as 
herding, pointing, retrieving and hunting (Spady and Ostrander, 2008). These breeds represent 
unique and closed breeding populations with great differences across the breeds, and limited 
variation within the breeds, and thus each breed has its own characteristic behaviour and 
morphology, even though they all have the same ancestor, the gray wolf (Canis lupus) 
(Boyko, 2011; Hall and Wynne, 2012; Spady and Ostrander, 2008). Thus the unique 
population history and breed structure of dog may facilitate genetic studies, and genes can be 
found in smaller study cohorts with fewer markers. Importantly, many anxieties, such as 
canine compulsive disorder, are breed specific suggesting strong genetic susceptibility 
(Hedhammar and Hultin-Jäderlund, 2007; Overall, 2000; Tiira et al., 2012). Finally, 
behavioural abnormalities can be measured and quantified to identify variation in the 
population for genetic correlation studies to pinpoint causative genomic regions and genes.  
Due to the high complexity of anxiety traits, there is a huge need for better markers for 
diagnostics. Thus novel, innovative and more powerful approaches are needed in order to 
unravel the molecular mechanisms underlying anxiety-like behaviour. A non-targeted 
metabolite profiling represents an important but yet less used approach in research involving 
dogs, which has all the potential to facilitate our understanding of canine anxieties. Non-
targeted metabolomics includes a comprehensive analysis of thousands of metabolites of a 
biological specimen simultaneously, providing a metabolite profile of an individual or any 
taken sample at a given time (Theodoridis et al., 2012; Zhou et al., 2012). It may give 
information about biochemical processes and biological networks, suggesting different 
pathogenic conditions. Non-targeted metabolomics is also very powerful method to identify 
biomarkers for diseases and to elucidate the differences in metabolite profiles between test 
groups. For a high-resolution analysis, liquid chromatography combined with mass 
spectrometry (LC-MS) is commonly used (Zhou et al., 2012). The aim of this study was to set 
up a pilot study for non-targeted metabolomics to investigate the possible differences of the 
metabolite profiles of anxious and non-anxious dogs to identify potential biochemical disease 
processes or candidate biomarkers for more accurate phenotyping upon further validation in 
larger anxiety cohorts in future. 
  
10 
 
2 REVIEW OF THE LITERATURE  
2.1 Anxiety-related conditions in dogs 
2.1.1 A general overview of canine anxieties 
Different kinds of fears, phobias and other anxiety-related conditions have become the most 
common behavioural problems among pet dogs worldwide (Gruen and Sherman, 2008; 
Pineda et al., 2014). An increasing number of dogs are particularly suffering from shyness 
against strangers, other dogs or novel situations, or fear of loud noises (Tiira and Lohi, 2014). 
The fear can be of a generalized nature, when the dog shows fear in several situations, or it 
can be more specific, when the fear is triggered by a particular stimulus. Also separation 
anxiety and generalized anxiety affect a large amount of dogs with an estimated 14% 
prevalence in the United States (Overall et al., 2001). 
A suitable and effective treatment of these conditions would be important since when left 
untreated, the fear reactions and feelings of anxiety can evolve beyond control, leading to a 
state of continuous distress. Fearful and anxious dogs may not only cause damage to 
themselves but also to their environment or people around them, and hence the affected dogs 
are regrettably often abandoned, relinquished to animal shelters, or even euthanatized due to 
their undesirable behaviour (Herron et al., 2008; Overall et al., 2001). Although anxious and 
fearful dogs respond at least partially to human anxiolytics, such as benzodiazepines, tricyclic 
antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs), often combined 
with behavioural therapy, there is a lack of knowledge of the exact molecular mechanisms 
causing anxiety and fearfulness among dogs (Gruen and Sherman, 2008). Thus, the discovery 
of molecular correlates for canine anxiety disorders would be highly desirable to improve the 
diagnostics and treatment of these pathological conditions in order to enhance the quality of 
life of these dogs and to reduce the number of dogs euthanatized or abandoned because of 
these behavioural problems. 
Anxiety is defined as an unpleasant emotional state, which is induced by a feeling of potential 
threat or danger (Bouayed et al., 2009; Gross and Hen, 2004; Herron et al., 2008). It is a 
normal and inherent trait, which helps an individual to cope in novel and challenging 
situations by triggering correct adaptive responses. As a short-term response to worry and 
fear, almost everyone encounters feelings of anxiety at some point of their life. But when the 
feeling of anxiety, however, comes persistent, overwhelming, irrational, inappropriate and out 
of proportion, it is considered as a pathological state. When it comes to that point, individual’s 
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quality of life and ability to adapt to novel and stressful situations can be impaired (Steimer, 
2002). Indeed, the pathological anxiety is usually a chronic state, and thus the long-lasting 
stress may have undesirable effects on immune cardiovascular and neuroendocrine systems 
(Dreschel and Granger, 2005). This type of pathological anxiety may be present, for example, 
in different phobias and separation anxiety in dogs.  
Fear is defined as an instinctual and distressing feeling, conserved among species, induced by 
stimulus which an individual finds as a threat, and thus just like anxiety, also fear can be 
considered as normal and inherent behaviour which is essential for adaptation and survival in 
novel situations (Hydbring-Sandberg et al., 2004). Fear and anxiety are thought to be distinct 
emotional phenomena, although they share relatively large proportion of common features. 
Indeed, fear is aroused by certain, known and present danger, whereas anxiety is thought to be 
a generalized response induced by unknown and/or only potential future threat (Steimer, 
2002). However, both fear and anxiety aim to protect the individual from observed threat – 
either real or potential – by inducing adaptive and defensive behaviour, such as active and 
passive coping strategies, including fight-or-flight response and freezing, respectively. Thus, 
one may also say that sometimes anxiety can be a result from unresolved fear, which has 
evolved as generalized anxiety reflected by constant feelings of potential danger. An anxious 
or fearful dog may express its feelings in several ways, and the responses vary according to 
the source of stimuli and the level of fear. In humans, however, anxiety is expressed in 
characteristic responses, including avoidance, vigilance and arousal, which are also common 
reactions in pet dogs (Dale et al., 2010; Gross and Hen, 2004; Hydbring-Sandberg et al., 
2004).   
 
2.1.2 Fearfulness  
As described in the previous section, fear is as a state induced by stimulus which an 
individual finds as a threatening, and thus it facilitates an individual to adapt novel and 
challenging situations, and protects individual from potential danger (Hydbring-Sandberg et 
al., 2004). However, responses to threatening situations and capability to controlling the fear 
varies among individuals, whereas some are more vulnerable than others. The level of fear is 
also dependent on the threatening stimulus, and the intensity of it. Thus dog’s reaction can 
vary from mild shyness to very powerful and intensive fearfulness when confronting the 
source of stimuli. A fearful or shy dog may suffer from social fear, which can be divided into 
stranger- or dog-directed fear (Svartberg, 2007). Dog can also be afraid of novel situations or 
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unfamiliar objects, categorized as non-social fear. Some dogs suffer from specific phobias, 
since they are afraid of one or two particular stimuli, such as cars or unfamiliar persons, for 
example, whereas some dogs are more vulnerable to develop fears and anxieties, and as a 
result they may develop general fear towards several objects. Indeed, the most fearful dogs 
can show both social and non-social fear, and these dogs are characterized by generalized 
anxiety, which highly interferes their everyday life. The most common reactions to fear 
towards strangers, other dogs and new environments include avoidance, escape, immobility or 
aggressive behavior, such as barking, growling or biting (Hydbring-Sandberg et al., 2004).   
Behaviour is affected by several factors. Environmental factors are known be contributing to 
the development of specific fears and phobias, since life experiences and events can have 
major impacts (Foyer et al., 2013). The role of environmental factors in the development of 
anxiety-related conditions in general is discussed more detailed in the chapter 2.2.4. Also 
genetics have a role since some are more vulnerable than others, and as an evidence of this, 
relatively high estimates of heritability for fear in dogs (0.49) have been suggested (Goddard 
and Beilharz, 1985). Genetic predispositions to anxiety disorders are discussed in chapter 
2.2.3.  
 
2.1.3 Sound sensitivity and noise phobia 
Sound sensitive dogs are vulnerable to loud noises of which gunshots, thunder and fireworks 
represent most common examples (Dale et al., 2010; Dreschel and Granger, 2005). The 
exposure to these noises can cause different kinds of responses in dog, including escaping, 
hiding, immobility, panting, pacing, trembling or vocalising, and these responses can vary 
according to the source of stimuli and the level of fear. Noise phobia is a severe state which 
can result from repetitive negative experiences of loud and scary noises, from a single highly 
traumatic exposure to close and intense noise, or from a situation in which the fear is left 
untreated, leading to a progress of a phobia. Normal fear towards loud noises persists only 
short-term after the noise stops, and the intensity of the fear reaction is proportional to the 
threat, whereas noise phobic dogs have more powerful fear reactions, which are 
disproportionate to the danger, and which continue after the noise has stopped. In the worst 
cases, the fear reaction can evolve beyond control, leading to a complete panic, when the dog 
may injure itself or destroy its surroundings. Consistent with that, it has been considered that 
panic can be one component of thunderstorm phobia (Overall, 2000).   
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Due to the very powerful fear reactions of noise phobic dogs, it is not exaggerated to say that 
the dog’s physical and mental health is threatened, knowing the fact that long-lasting stress 
has undesirable effects on immune, cardiovascular and neuroendocrine systems (Dreschel and 
Granger, 2005). Short-term stress facilitates body function and adaptation to new situations by 
activating the sympathetic nervous system and the hypotalamic-pituitary-adrenal (HPA) axis, 
but when the stress response becomes constant, the persistent activation of these systems can 
lead to a worsen body function due to high blood pressure and heart rate, release of cortisol 
from the adrenal cortex by HPA axis activation, and secretion of catecholamines adrenaline 
and noradrenaline from the adrenal medulla (Hydbring-Sandberg et al., 2004). Indeed, 
Hydbring-Sandberg et al. (2004) found in their study that dogs who were fearful of gunshots 
had increased heart rate and hematocrit level, and elevated plasma levels of cortisol, 
progesterone, vasopressin and endorphins during and after gunshot, when compared to dogs 
with no fear. These results indicate that exposure to gunshots, and maybe to other loud and 
sudden noises, can cause serious stress to the dog predisposing it to the detrimental 
physiological consequences. 
High heritability estimates for noise phobia (0.56) indicate strong genetic component (van der 
Waaij et al., 2008). Overall (2001) has also found that great proportion of dogs suffering from 
noise phobia have also signs of other anxiety-related conditions, including separation anxiety, 
and thus these two pathological conditions could be related at the biological level. The 
probability that dog suffers from both of these conditions was relatively high, 0.88 for a noise 
phobic dog to have also separation anxiety, and 0.86 for a dog suffering from separation 
anxiety to have also noise phobia. 
 
2.1.4 Other anxiety-related conditions in dogs 
In addition to fearfulness/shyness and noise phobia, many dogs are suffering from several 
other anxiety-related diseases, such as separation anxiety, compulsive disorder, and maybe 
also from post-traumatic stress disorder, although the latter one is not a fully recognized 
behavioural problem among dogs (Overall, 2000). 
Separation anxiety is described as a one of the most common behavioural disorders in dogs, 
and in which the dog experiences very powerful anxiety and distress when separated from his 
owner or left alone (Overall, 2000; Overall et al., 2001). Common symptoms are increased 
mobility or immobility, vocalization, urination, defecation, and destruction of furniture or 
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other objects of the house which can result in self-injuring. The symptoms of separation 
anxiety are non-specific, and sometimes a dog left alone may destroy its surroundings or 
vocalize because the dog is bored in the lack of activities, not because it would miss its 
owner(s). Thus an accurate diagnosis is often difficult. Due to the severity of the symptoms, 
dogs suffering from separation anxiety has been regrettably often abandoned or euthanatized 
(Herron et al., 2008; Overall et al., 2001). Fortunately dogs suffering from separation anxiety 
are treated with human anxiolytes, such as TCAs and SSRIs, with positive outcomes 
nowadays, and this has reduced the number of euthanized or abandoned dogs.  
Canine compulsive disorder (CCD) is analogous condition to human obsessive compulsive 
disorder (OCD), an anxiety-related neuropsychiatric disorder, and CCD is characterized by 
bouts of repetitive behaviour, such as tail chasing, pacing, chasing of light/shadows or 
“invisible flies”, licking, freezing, staring, and flank sucking (Overall, 2000; Tiira et al., 
2012). Similar to human OCD, CCD interferes the quality of everyday life. The onset of CCD 
usually appears during the time of social maturity, and if the condition is left untreated, the 
symptoms get worse while ageing. CCD is treated with positive outcome with TCAs and 
SSRIs, drugs used also treatment of human anxiety disorders (Gross and Hen, 2004; Overall, 
2000; Tiira et al., 2012). The aetiology of this disorder is unknown, although genetics is 
suggested to have a major role, since CCD is more common in specific breeds and moreover, 
some of the single compulsions are highly breed-specific (Hedhammar and Hultin-Jäderlund, 
2007; Overall, 2000; Tiira et al., 2012).  
 
2.2 The biological background of anxiety 
2.2.1 The development and onset of anxiety-related disorders is affected by many 
factors 
Most behavioural traits, and thereby also behavioural diseases, such as anxiety-related 
disorders, are complex and characterized by involvement of many genes and environmental 
factors. Genetics are known to have a role, and moderate to high estimates of heritability have 
been discovered for pathological anxiety both in humans and dogs. The interaction between 
genetic and environmental factors increases the risk for development of behavioural 
abnormalities. Environmental factors can change the expression of genes involved in the 
neurochemistry of anxiety during the early development, which is a highly vulnerable time for 
disruptions. This can lead to significant changes in the function of the biochemical and neural 
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networks of fear and anxiety, resulting in anxiety-related pathologies (Steimer, 2002). In this 
section, the basis of the neurobiology of anxiety, such as affected neurotransmitter systems 
and brain areas, are reviewed based on human, rodent, primate and canine studies. Also the 
roles of genes, environment factors, and oxidative stress in the development of anxiety-related 
conditions are shortly discussed.  
 
2.2.2 The neurobiology of anxiety 
Anxiety disorders are characterized by disturbances in the normal neural networks and 
circuits of fear and anxiety. This results in overactivation of specific brain regions and circuits 
involved in the fear response, even when the danger already has diminished. Several 
neurotransmitter systems, such as serotonergic, dopaminergic, noradrenergic, and GABAergic 
systems, and brain regions, such as amygdala, hypothalamus and prefrontal cortex, are 
affected in pathological anxiety (Steimer, 2002).  
The neuroanatomy of anxiety 
Emotions, such as fear and anxiety are known to activate particular brain regions. The crucial 
role of amygdala has been highlighted in the development of anxiety-related pathologies 
(Davis, 1992). The amygdala is known to have a primary role in the perception of fear, fear 
response, and learned fear memory, and it has several subdivisions, such as lateral (LA), 
basolateral (BA) and central (CeA) nucleus of amygdala. They all have distinct roles in fear 
expression, since LA and BLA are known to be the regions receiving sensory information 
from the thalamus, the hippocampus and the prefrontal cortex (PFC), and forwarding this 
information to CeA, which in turn projects to several brain regions, such as lateral 
hypothalamus (LH), paraventricular nucleus of hypothalamus (PVN), locus ceruleus (LC), 
and parabrachial nucleus (PBN), causing the characteristic symptoms of fear and anxiety (Fig. 
1). BLA is also suggested to be involved in the development of specific phobias, and since the 
amygdala regulates social behaviour, it has been suggested that disturbances in the function of 
the amygdala may be involved in social anxiety (Steimer, 2002).  
 
Projections from CeA to LH are responsible for the activation of the sympathetic autonomic 
nervous system causing the characteristic symptoms of fear, including increased heart rate, 
blood pressure and perspiration, while projections to PVN cause the secretion of 
corticotropin-releasing hormone (CRH) from PVN, which further stimulates the secretion of 
adrenocorticotropic hormone (ACTH) from anterior pituitary activating adrenal cortex to 
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produce cortisol, the main stress hormone (Davis, 1992; Steimer, 2002). This phenomena is 
called as hypothalamic-pituitary-adrenal (HPA) axis, which regulates stress responses, mood  
and emotions, for example, and the axis is known to be hyperactive in a state of anxiety or 
fear. During stress or traumatic events the levels of cortisol are significantly elevated as a 
result from the activation of the HPA-axis. In normal situation, the negative feedback of CRH 
and ACTH secretion by cortisol decreases the activity of HPA-axis, whereas in individuals 
suffering from anxiety-related disorders, this negative feedback is inhibited, which results in 
increased cortisol levels. Indeed, it has been demonstrated that prenatal and early postnatal 
stress can permanently alter the function of HPA-axis, resulting an increased vulnerability for 
development of anxiety disorders in later life (Bravo et al., 2014; van den Hove et al., 2011). 
The activity of HPA-axis is also modulated by the amygdala and the hippocampus, which are 
known to be stimulating and inhibiting, respectively, the activation of HPA-axis (Martin et 
al., 2010). Thus the neuroendocrine responses to fear are possibly mediated by this 
interaction.  
 
The autonomic symptoms of fear and anxiety, such as bradycardia, defecation and urination, 
are a result from the activation of autonomic nervous system, since CeA directly projects to 
the dorsal motor nucleus of the vagus nerve (DMN) (Steimer, 2002). Direct projections of 
CeA to PBN causes symptoms related to respiration, such as panting, while projection of CeA 
to the caudal reticulopontine nucleus (RPC) is responsible for the initial startle response when 
exposed to fearful stimuli. The “fight, flight or fright” response, characteristic for fear, results 
from projection of the amygdala to the periaqueductal gray (PAG). CeA also projects to the 
locus ceruleus (LC), which is the primary site of noradrenaline synthesis in the brain, and thus 
it has been suggested that LC is an important brain region involved into anxiety. LC further 
projects to several brain regions involved in fear and anxiety, such as PVN, PFC, PAG, the 
hippocampus, the thalamus, the nucleus tractus solitaries (NTS), the bed nucleus of the stria 
terminalis (BNST), and CeA. BNST forms a part of the “extended amygdala” which 
integrates the information incoming from the amygdala and the hippocampus. CeA projects 
also to BNST which in turn projects to PVN and LH mediating the neuroendocrine responses 
to fear (Steimer, 2002).  
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Figure 1. A schematic picture of the major brain circuits involved in anxiety and fear. The 
amygdala is the key structure of the limbic system, and it has primary role in the perception of fear, 
fear response, and learned fear memory. The lateral nucleus of amygdala (LA) and the basolateral 
nucleus of amygdala (BLA) receive sensory information about stimuli via thalamus, precortex (PFC), 
and hippocampus, whereas the central nucleus of amygdala (CeA) projects to several brain areas, 
including paraventricular nucleus (PVN) of hypothalamus, lateral hypothalamus (LH), the dorsal 
motor nucleus of the vagus nerve (DMN), caudal reticulopontine nucleus (RPC), parabrachial nucleus 
(PBN), and periaqueductal gray (PAG), which produce the characteristic symptoms of fear and panic. 
CeA also projects to locus ceruleus (LC), a primary site for noradrenaline synthesis in the brain, 
triggering noradrenergic responses. Adapted from Steimer (2002). 
 
Neurotransmitters of anxiety 
Several neurotransmitter systems, such as GABAergic, noradrenergic, and serotonergic 
systems, are suggested to be involved in fear and anxiety since they are known to regulate the 
neuroanatomical circuits of fear and anxiety previously described. Disturbances in these 
systems, due to genetics, environment or the interaction of these, may result in altered levels 
of necessary neurotransmitters and neuropeptides, leading to unwanted changes in behaviour.  
 
GABAergic system 
γ-Aminobutyric acid (GABA), a main inhibitory neurotransmitter in the brain, is suggested to 
have highly important role in anxiety, since benzodiazepines, one of the most effective 
anxiolytes, are observed to stimulate the function of GABAA-receptors, and especially the 
GABAA-receptor α2 subunit seems to be responsible for the anxiolytic affects (Gross and Hen, 
2004; Martin et al., 2010; Pineda et al., 2014; Steimer, 2002). Moreover, the fact that 
benzodiazepines, such as alprazolam, diazepam and clorazapate dipotassium are used in the 
treatment of storm phobia, separation anxiety, noise phobia and other anxiety-related 
behavioural abnormalities in dogs, in addition to anxiety disorders, such as generalized 
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anxiety (GAD), panic disorder and social phobia in humans, with positive outcomes 
demonstrates that GABAergic system has an important role in the development of anxiety-
related behaviour, and that the system is conserved at least among higher mammals (Crowell-
Davis et al., 2003; Gross and Hen, 2004; Herron et al., 2008; Pineda et al., 2014). Stress is 
known to modulate the function of GABAA-receptors, and rat studies suggest that particularly 
early-life stressors, such as maternal separation or different handling during early postnatal 
period, reduce the levels of GABAA-receptors in the LC and the NTS, and the levels of 
central benzodiazepine (CBZ) receptor sites in LC, NTS, the frontal cortex, CeA, and LA, 
affecting to the development of GABAergc system (Caldji et al., 2000).  
 
Noradrenergic system 
Noradrenaline is a neurotransmitter known to be involved in the regulation of cognition, 
learning, memory, sleep, stress response, and vigilance (Brunello et al., 2003). Fearful or 
stressful stimuli is known to increase the noradrenaline release in the brain via function of the 
CeA that directly projects to LC, a primary site of noradrenaline synthesis in the brain, which 
further projects to several brain regions, such as PVN, PFC, PAG, the hippocampus, the 
thalamus, NTS, BNST and CeA, known to be involved in the pathology of anxiety, clearly 
demonstrating that noradrenergic system has major role in transmitting the fear responses.  
(Fig. 1) (Brunello et al., 2003; Davis, 1992; Steimer, 2002). Rat studies have also implicated 
that an α2-adrenergic receptor antagonist, yohimbine, increases the secretion of noradrenaline 
in the brain, resulting in increased levels of anxiety (Figlewicz et al., 2014; Yeung et al., 
2013). The fact that noradrenergic agents, such as lofepramine, have also been successfully 
used in the treatment of anxiety disorders in humans indicates the crucial role of dysregulation 
of noradrenergic system in the psychopathology of several psychiatric disorders, such as 
depression and anxiety-related diseases (Brunello et al., 2003).  
 
Serotonergic system 
Serotonin (5-hydroxytryptamine; 5-HT) is a neurotransmitter, created from an essential amino 
acid tryptophan, having a significant role in regulating not only several neuropsychological 
processes, but also other biological networks, such as cardiovascular and gastrointestinal 
systems (Berger et al., 2009). The status of serotonin and the serotonergic system in the 
development of behaviour, regulation of emotions, and pathogenesis of numerous 
neuropsychiatric diseases is nowadays well known, and disturbances in the normal function of 
the serotonergic system, especially during early postnatal period, have discovered to be 
crucial in the development of behaviour, and thus these networks have important roles in the 
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psychopathology of several anxiety-related diseases (Bravo et al., 2014). The dorsal raphe 
nucleus (DRN) and the median raphe nucleus (MRN) are the main brain regions containing 
serotonergic cells and projecting to other brain regions, such as amygdala and hippocampus, 
respectively, and these connections may be responsible for the effects of 5-HT to behaviour, 
since serotonergic system is suggested to modulate the fight-or-flight response via these 
pathways. 
5-HT has 14 receptor subtypes with distinct functions, most of which are G-protein coupled 
receptors, and especially the serotonin 1A (5-HT1A) receptor has described to have a major 
role in the development and regulation of behaviour and emotions, since it mediates the 
effects of 5-HT to anxiety, fear and stress by regulating the release of 5-HT (Bravo et al., 
2014; Parks et al., 1998). Thus altered 5-HT1A receptor expression, resulting from genetic 
variation or environmental factors, may result in disturbances in serotonergic function, 
predisposing to anxiety-related disorders. In the brain, there is two distinct populations of 5-
HT1A receptors; 5-HT1A presynaptic autoreceptors and 5-HT1A postsynaptic heteroreceptors. 
5-HT1A autoreceptors are expressed in the serotonin neurons in DRN and MRN, and they 
regulate the 5-HT levels by mediating negative feedback of the serotonergic firing, whereas 5-
HT1A heteroreceptors are expressed in non-serotonin neurons in brain regions regulating 
anxiety and fear, such as the hippocampus, amygdala, and PFC, mediating the responses of 
these brain regions to the released 5-HT. There are conflicting results from the roles of these 
two receptor population’s functions in anxiety, since some studies suggest a primary role for 
5-HT1A autoreceptors (Richardson-Jones et al., 2011), while others demonstrate that 5-HT1A 
autoreceptors are not sufficient enough to induce anxiety-like behaviour in the absence of 5-
HT1A heteroreceptors  (Piszczek et al., 2013). Thus the roles of these two distinct 5-HT1A 
receptor populations in anxiety remain unclear.  
SSRIs, anxiolytes that are suggested to increase the extracellular levels of 5-HT by blocking 
the action of 5-HT transporter (5-HTT), a protein transporting the released 5-HT from 
synapses to pre-synaptic neurons, are used in treatment of several anxiety disorders, such as 
GAD, OCD, panic disorder, post-traumatic stress disorder (PTSD), and social phobia in 
humans, and also dogs suffering from CD have been treated with SSRIs with positive 
outcome (Gross and Hen, 2004; Tiira et al., 2012). This indicates that also alterations in the 
expression of 5-HTT may have an impact on the vulnerability to anxiety. Gene discoveries 
related to the serotonergic system further supports the fact that abnormal serotonergic 
function may be highly significant predisposing factor for the development and regulation of 
mood and behaviour. These genetic variations are discussed in the section 2.2.3. 
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2.2.3 Anxiety genetics 
There have been several attempts to investigate and reveal the genetic basis of anxiety 
disorders in human but the heterogeneity and complexity of these pathological conditions has 
made the studies challenging, and due to that the results are conflicting (Spady and Ostrander, 
2008). For the same reason, there is also a pause of gene discoveries related to anxiety 
disorders and other behaviour abnormalities in dogs. It has also been suggested that the set of 
underlying genetic factors may be generally shared among different anxiety-related disorders, 
since the candidate genes have been same across different diseases (Martin et al., 2010). A 
significant familiar aggregation has been discovered in GAD, OCD, panic disorder, and 
phobias in humans, indicating a genetic basis for these disorders, and similar effect can also 
be observed among dogs, since some anxieties are highly breed specific (Hettema et al., 
2001). Also the biological background of behaviour and behavioural abnormalities may be 
conserved among species, since a broad personality trait, named as boldness or shyness-
boldness dimension, has been observed not only in dogs and humans but also in other 
mammals (Kagan et al., 1988; Lindblad-Toh et al., 2005; Saetre et al., 2006; Svartberg and 
Forkman, 2002). Ever since the dog genome sequence was revealed in 2005 (Lindblad-Toh et 
al., 2005), there have been a few candidate gene studies of dog behaviour, but unfortunately 
many of them have failed. The genes of most interest for behavioural genetic studies, are 
those encoding thce members of neurotransmitter and neuropeptide systems, known to be 
important in the development and regulation of fear, anxiety and aggression (Spady and 
Ostrander, 2008).  
Genes in the serotonergic system play a significant role in the pathogenesis of anxiety-like 
conditions (Bravo et al., 2014; Parks et al., 1998; Strobel et al., 2003). Several rodent and 
human studies have discovered connections between different serotonin receptors and 
increased anxiety-like behaviour. One of the most investigated gene encodes the serotonin 1A 
(5-HT1A) receptor (Strobel et al., 2003). Indeed, panic disorder, PTSD and depression have 
been associated with decreased binding properties of the 5-HT1A receptor (Gleason et al., 
2010). Moreover, a single nucleotide polymorphism in the promoter of 5-HT1A receptor gene 
has been associated with anxiety-related behaviour in humans (Strobel et al., 2003), and also 
5-HT1A knockout mice show increased levels of anxiety and stress (Parks et al., 1998). 5-
HT1A receptors are also known to mediate the effects of anxiolytes and antidepressants further 
supporting the highly crucial role of 5-HT1A receptor function, and thus the role of 5-HT and 
serotonergic system in mood and behaviour (Strobel et al., 2003). Moreover, Bravo and 
colleagues (2014) showed that stress during the early postnatal period of mice is capable of 
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causing permanent alterations in the expression of both 5-HT1A receptor and 5-HTT genes in 
amygdala and DRN, highly important regions of regulating behaviour and mood, possibly 
contributing to the development of anxiety-related behaviour later in life. In addition, Gleason 
and colleagues (2010) discovered that in mice the knockout of 5-HT1A receptor gene of the 
mother during pregnancy caused increased anxiety-like behaviour in puppies despite the 
puppies own 5-HT1A receptor deficiency suggesting that also nongenetic mechanisms may be 
highly responsible for the transmission 5-HT1A receptor deficiency. 
In addition to 5-HT1A receptor, also serotonin transporter (5-HTT), a protein that regulates 5-
HT neurotransmission by transporting 5-HT from synapses to pre-synaptic neurons, has been 
revealed to mediate the effects of serotonin on mood and behaviour, since the anxiolytic 
effects of SSRIs are based on blocking the 5-HTT activity, and patients with anxiety disorders 
are also observed to have decreased PFC binding of 5-HTT (Araragi and Lesch, 2013; Gross 
and Hen, 2004; Wellman et al., 2007). Moreover, the 5-HTT gene is known to have a repeat 
length polymorphism in its promoter region, and individuals with the short (s) variants, which 
is known to reduce the 5-HTT expression, show increased anxiety-like behaviour when 
compared to individuals with the long (l) variants (Lesch et al., 1996). Furthermore, s/s and s/l 
individuals are also observed to more likely become depressed when exposed to stress during 
early childhood than l/l individuals (Caspi et al., 2003). These results demonstrate that the 
short allele of the 5-HTT polymorphism increases the risk of depression only for patients who 
have exposed to stressful events, whereas the long allele would have protective effects. 
Rhesus monkeys exhibit analogous 5-HTT repeat length polymorphism, and as in humans, 
also monkeys with short allele show increased anxiety-like behaviour, and interestingly, early 
adverse experiences were observed to interact with the gene polymorphism in monkeys too 
(Bennett et al., 2002). Also heterozygous 5-HTT s/l mice show increased depressive-like 
behaviour when exposed to prenatal stress (van den Hove et al., 2011). Furthermore, an 
association between the 5-HTT polymorphism and an increased risk for PTSD is also 
suggested (Lee et al., 2005). 
Tryptophan hydroxylase-2 (TPH2) is an important enzyme catalysing the serotonin synthesis 
from tryptophan in the brain, and it is suggested to have role in the pathogenesis of anxiety, 
aggression and depression (Araragi and Lesch, 2013; Waider et al., 2011). Polymorphisms in 
gene encoding this enzyme are observed to have major impacts on the serotonergic system 
both in human and mice, and thus variation of this gene may influence on the pathogenesis of 
anxiety-related disorders (Waider et al. 2011). Indeed, TPH2 polymorphisms have been 
connected to mood disorders, such as OCD, in humans, and a general association between 
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anxiety-related traits and variants of TPH2 has also been demonstrated. Interestingly, a recent 
study shows however conflicting results, demonstrating that reduced activity of TPH2 is not 
sufficient to cause anxiety-like behaviour and significant reductions in 5-HT levels of the 
brain in mice because of the compensation between 5-HT degradation and 5-HT synthesis 
(Mosienko et al., 2014).  
The number of studies investigating canine behavioural genetics is low, and most of them are 
concerning aggression and impulsive behaviour rather than anxiety-related behavioural 
problems. There have been a few attempts to connect polymorphisms in genes encoding for 
serotonergic system (Liinamo et al., 2007; Vage et al., 2010; van den Berg et al., 2005) and 
dopaminergic system (Hall and Wynne, 2012; Hejjas et al., 2007; Hejjas et al., 2009) with 
increased human-directed aggression and impulsive behaviour, but so far only dopamine 
receptor D4 (DRD4) has been found to have a clear association with abnormal behaviour 
(Hejjas et al., 2007; Hejjas et al., 2009). In humans, links between DRD4 and OCD have been 
suggested (Millet et al., 2003). Associations between polymorphisms in the solute carrier 
family 1 member 2 (SLC1A2) and catechol-O-methyltransferase (COMT) genes and activity 
level of dogs were observed in a study of Labrador retrievers used for guide dogs for blinds 
(Takeuchi et al., 2009). SLC1A2 encodes a glutamate transport protein, and is linked to 
aggression, whereas COMT is known to be involved into neurotransmitter metabolism, and it 
has also been implicated in schizophrenia, panic disorder and OCD in humans.  
 
2.2.4 Environmental factors and anxiety  
It is well known that environmental factors, along with genetics, have a great influence on the 
behaviour and personality of an individual among species. Especially the early postnatal 
period is highly crucial time for development of behaviour, since it is the time when the 
central nervous system develops and matures, and thus is highly vulnerable for disruptive 
factors. Early-life stress, traumatic experiences, and changes in maternal care are well known 
risk factors for development of anxiety-like behaviour and mood disorders in humans, 
rodents, and nonhuman primates, and similar observations are also made in dogs, since 
traumatic events and poor socialization during puppyhood may have long-term effects on 
dog’s personality and behaviour, and can lead to fears or phobias later in life (Bennett et al., 
2002; Bravo et al., 2014; Foyer et al., 2013). Furthermore, it is also now observed that even 
litter size and composition, season of birth, and the prenatal environment can permanently 
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modulate dog’s behaviour by altering the regulation of genes that control behaviour (Foyer et 
al., 2013; van der Waaij et al., 2008).  
In rats, maternal behaviour influences to gene expression of puppies by DNA methylation and 
other structural modifications, called as epigenetic modifications, and these changes can have 
long-term heritable effects on the behaviour of the puppies (Meaney and Szyf, 2005). In a 
study of German shepherd dogs, no significant correlations between mother’s genetic or 
environmental effects and puppies’ behaviour later in life were found, whereas the litter was 
observed to have a larger impact (Strandberg et al., 2005). In a study by Pierantoni and 
colleagues (2011), canine puppies separated from the mother and the litter at 30 to 40 days 
developed more behaviour problems than puppies raised with their mother and littermates 
untilthe age of two months, indicating that the stress experienced by puppies during the early 
postnatal period may be sufficient to alter behaviour in a permanent manner in dogs too. This 
is in consistent with observations made in humans since excessive stress during childhood 
increases the risk of development of anxiety disorders, such as PTSD in adulthood (Gross and 
Hen, 2004). Furthermore, emotional or physical stress experienced by the mother during 
pregnancy, also called as prenatal stress, is a known risk factor for the development of 
anxiety-like disorders later in life, since it may cause disruptions in the normal function of 
HPA-axis resulting in increased anxiety-like behaviour (van den Hove et al., 2011).  
Nutrition is known to have an influence on behaviour, since studies suggest, for example, that 
low levels of dietary omega-3 polyunsaturated fatty acids (PUFAs) may predispose for 
depression and anxiety in humans (Hennebelle et al., 2014; Liu et al., 2013). Dietary fatty 
acid composition has direct effects to the lipid concentrations and constitutions in brain, since 
the grey matter in central nervous system consists of dietary derived PUFAs, including 
linoleic acid (C18:2 or LA) and α-linolenic acid (C18:3 or ALA), which is an omega-3 PUFA 
(Bosch et al., 2007), and thus it may have an impact on the psychopathology of mood 
disorders. In addition to humans, also the mood and behaviour of rodents is suggested to be 
controlled by omega-3 PUFAs, since some studies have found a connection between reduced 
omega-3 PUFA concentrations in diet and increased aggressive, anxiogenic and stress-related 
behaviour, whereas omega-3 PUFA enriched diet was associated with reduced stress and 
anxiety (Carrie et al., 2000; DeMar et al., 2006; Takeuchi et al., 2003). In addition to dietary 
lipids, also dietary proteins and amino acids may have significant effect on behaviour, since 
some essential amino acids are precursors of highly important neurotransmitters, such 
tryptophan is a precursor of serotonin (Bosch et al., 2007). Studies in several animal species, 
including rats and monkeys, have shown that a high-tryptophan diet has reduced aggressive 
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behaviour of individuals. It has also been revealed that dietary tryptophan can improve coping 
in stressful situations, since decreased plasma cortisol and noradrenaline levels were 
measured after stressful events in pigs receiving tryptophan supplementation (Koopmans et 
al., 2005). Dietary tryptophan may enhance serotonin-mediated function, since serotonin 
levels are directly proportional to the tryptophan concentrations. The knowledge about 
connections between nutrition and anxiety-like behaviour in dogs is limited, but based on 
rodent and human studies, it can be assumed that dietary lipids may play a role in canine 
behaviour too, since canine nutrition shares similarities with human nutrition.  
 
2.2.5 Oxidative stress and anxiety 
Oxidative stress is a state caused by an accumulation of reactive oxygen species (ROS), when 
the balance between pro- and antioxidant systems of the cell is disturbed (Bouayed et al., 
2009).  This results in a damage of several cellular components, such as DNA, lipids, nucleic 
acids and proteins, and in increased levels of pro-inflammatory cytokines. Indeed, oxidative 
stress is speculated to be involved in several pathological conditions, including 
atherosclerosis, cardio-vascular disorders, diabetes, cancer, neuropsychiatric diseases and 
autoimmune diseases. Recently, significant associations between oxidative stress and anxiety 
have been revealed, and that is not surprise when considering the features and the constitution 
of brain. High O2 consumption, poor antioxidant defence, and especially the high 
concentration of lipids in the brain are all characteristics that make the brain very vulnerable 
to oxidative stress and free radicals. Recently, several studies have demonstrated associations 
between inflammation, potentially initiated by oxidative stress-induced increase in pro-
inflammatory cytokine production, and both anxiety disorders and depression (Dowlati et al., 
2010; Liukkonen et al., 2011; Spitzer et al., 2010; Vogelzangs et al., 2013; Zunszain et al., 
2012), but inflammation can also be a cause of oxidative stress (Maccioni et al., 2009).  
Hovatta and colleagues (Hovatta et al., 2005) were the first to identify the link between 
anxiety-like behaviour and oxidative stress in their behavioural study of inbred mice strains. 
They found that in the cingulated cortex of the brain altered expression of glutathione 
reductase 1 and glyoxalase 1, genes that have a significant role in the antioxidant system, 
resulted also in changes of anxiety-like behaviour, in a manner that overexpression of these 
genes increased anxiety-like behaviour, whereas inhibition of glyoxalase 1 by siRNA resulted 
in decreased anxiety.  
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The study of predator exposure animal model of PTSD, conducted by Wilson and colleagues 
(2013), revealed increased levels of oxidative stress and inflammation in rats. Notably, the 
levels of oxidative stress were not only elevated in the brain (hippocampus, PFC, amygdala), 
but also in the adrenal glands and blood after exposure to highly stressful stimuli. These 
results implicate that the oxidative stress and inflammation in PTSD may not be restricted to 
brain only. However, it is not clear if the damage caused by oxidative stress and inflammation 
is a cause or a result of PTSD.  
There is evidence that oxidative stress plays a main role in the pathology of schizophrenia too 
(Prabakaran et al., 2004). Also several studies in trait anxiety mice have demonstrated that 
high anxiety-related behaviour (HAB) mice are characterized by increased oxidative stress 
when comparing to normal (NAB) or low (LAB) anxiety-related behaviour mice (Filiou et al., 
2011; Filiou et al., 2014; Zhang et al., 2011). Similarly there have been suggested connections 
between disrupted oxidative metabolism and OCD and panic disorder in humans (Kuloglu et 
al., 2002a; Kuloglu et al., 2002b). 
 
2.3 Dog as a model animal for human diseases 
2.3.1 Why bother dog? 
The value of the domestic dog (Canis familiaris) as a natural animal model for human 
diseases has recently been noticed, and indeed, it is an ideal and innovative model to 
investigate different diseases due to its unique population history, breed structure, and 
similarity to human behaviour and physiology (Overall, 2000; Saetre et al., 2006). It is widely 
believed that the dog has the honour to be the first species to be domesticated, and nowadays 
the breeding of dogs has led to the existence of more than 350 distinct breeds specifically 
developed for different tasks, each of these breeds representing unique and closed breeding 
populations that have characteristic behaviour and morphology (Hall and Wynne, 2012; 
Spady and Ostrander, 2008).  
When compared to rodents, the classic animal models, the use of the dog as a model for 
human diseases has many advantages (Overall, 2000; Saetre et al., 2006; Spady and 
Ostrander, 2008). First, the dog is a large animal, and thus physiologically closer to humans, 
and diseases tend to develop in a more similar way in dogs than in rodents. Indeed, it has been 
demonstrated that 352 of 649 canine diseases may be potential models for human diseases 
(Online Mendelian Inheritance in Animals, OMIA, http://omia.angis.org.au/home/). When it 
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comes to behavioural studies, rodent models suffer mostly because in rodents avoidance 
behaviour is considered to be normal due to their status as prey animals, whereas such 
behaviour in humans and dogs is considered as pathological (Overall, 2000). Behavioural 
abnormalities also occur naturally in dogs, whereas the same conditions have to be induced or 
bred in rodents (state and trait anxiety rodent models). The domestic dog has a unique 
population history and breed structure that facilitates genetic studies due to the high levels of 
homogeneity among individuals within many dog breeds (Hall and Wynne, 2012; Lindblad-
Toh et al., 2005). Thus genes can be found in smaller study cohorts with fewer markers. Most 
importantly, many diseases or traits are breed specific suggesting strong genetic 
susceptibility. Also the facts that domestic dogs have shared the same environment with 
human for a long time and are often treated with human drugs with positive outcomes, 
confirm that the dog is a highly valuable species as a model animal for human disease study.  
An excellent example of how genetic studies in dogs can also inform human diseases include 
a study of canine narcolepsy (Lin et al., 1999). This study revealed that mutation in the 
hypocretin receptor 2 gene (HCRTR2) caused canine narcolepsy in Doberman pinchers, and 
this finding led to several studies of the entire hypocretin system in human narcolepsy and 
subsequent development of new treatment option. This truly proves that studies of common 
human diseases can be facilitated by studies in dogs. However, it is important to note that no 
animal model, not even a dog, can ever fully mimic the human pathological condition that it is 
imitating.  
 
2.3.2 Dog as a model for human psychiatric conditions 
Psychiatric disorders in humans and their analogous conditions in dogs (Table 1), called as 
behavioural disorders, are likely to be the most complex pathological conditions, and also 
very poorly understood (Overall, 2000). Elucidation of the biological backgrounds of 
behavioural problems in dogs will not only facilitate diagnostics and treatment of canine 
behavioural disorders, but it would also enhance our knowledge and understanding of 
behaviour disorders in humans also. Pharmacological studies have demonstrated that canine 
anxieties are treated with positive outcomes with human anxiolytes, such as benzodiazepines 
and SSRIs (Crowell-Davis et al., 2003; Gruen and Sherman, 2008; Overall, 2000). This 
clearly suggests that the underlying biochemical mechanisms in anxieties may be shared in 
dogs and humans. Thus, dog may be an excellent model to facilitate our understanding of the 
molecular backgrounds of anxiety related conditions across species.  
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Table 1. Potential analogous or homologous behavioural pathological conditions in dogs and 
humans. Adapted from Overall (2000).   
Condition in dogs Condition in humans 
Canine cognitive dysfunction Alzheimer's disease 
Canine dominance aggression Impulse control diseases 
Canine PTSD PTSD 
Canine separation anxiety 
Social anxiety, separation anxiety, 
generalized anxiety 
CD OCD 
Noise phobias (panic disorder) Panic disorder 
Social phobia Social phobia 
 
2.4 Non-targeted metabolomics 
2.4.1 What is non-targeted metabolomics? 
Non-targeted metabolomics, also called as untargeted metabolomics or global metabolite 
profiling, is a comprehensive analysis of as wide array as possible of small-molecule 
metabolites (< 1800 Da) of a biological system, providing an entire metabolite profile of an 
individual or any taken sample at a given time (Bowen and Northen, 2010; Theodoridis et al., 
2012; Xiao et al., 2012; Zhou et al., 2012). It aims to detect, quantitate and identify the whole 
metabolome of a biological system and is often used to elucidate differences in the metabolite 
profiles between test groups. Non-targeted metabolomics may help us to understand the 
biochemical processes and biological networks in complex systems, and thus facilitate 
diagnostics and enable treatment of diseases, as well as identify novel biomarkers for 
diseases. It is an ideal method for helping us to understand the complex effects of 
environment and lifestyle on pathophysiological conditions in a hypothesis-free manner. The 
number of metabolomics studies has significantly increased in recent years, and this is not a 
wonder when taken into consideration all the advantages and applications of this particular 
method. Additionally, data from metabolomics studies can be complemented by data from 
genomics, transcriptomics and proteomics, which all are part of the “omics” cascade and 
systems biology, in order to obtain more comprehensive and all-encompassing data from a 
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particular system (Fig. 2) (Dettmer et al., 2007). Metabolism is a series of chemical reactions 
in a biological system, and metabolites are molecules transformed during metabolism. The 
advantage of metabolomics when compared to genetic studies is that metabolomics studies 
are demonstrated to give information that is closer to phenotype and thus directly informative 
regarding the physiological status of the taken sample. 
 
 
Figure 2. The “omics” cascade from genes, transcripts, proteins and metabolites to phenotype. 
As can be seen, the proteomics and especially metabolomics are closer to phenotype, and thus they are 
suggested to give more detailed information about phenotype than genetic studies. Adapted from 
Dettmer et al. (Dettmer et al., 2007).  
 
Non-targeted metabolite profiling is distinct from targeted metabolite analytics which aim to 
detect particular compounds of interest, related to specific molecular pathways, from 
biological samples (Dunn et al., 2013; Patti et al., 2012). This kind of approach can be very 
effective when the study is driven by a specific hypothesis in contrast to untargeted 
experiments. Naturally, the number of detected metabolites is also significantly lower in 
targeted studies when comparing to global metabolite profiling. One major difference 
between these two analyses is the identification process of detected metabolites: the identities 
of detected compounds are unknown in untargeted studies, and the chemical identities must 
be resolved, whereas the metabolites detected from targeted analysis are known. Thus, 
targeted metabolomics studies are more straightforward and rapid than untargeted approach, 
but they are not as suitable to discovery studies as untargeted methods. 
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Metabolomics is a very little utilized approach among canine studies, although some 
metabolomics studies have been performed for example in order to investigate canine bladder 
cancer, or dietary metabolism differences across breeds (Beckmann et al., 2010; Zhang et al., 
2012). To author’s knowledge there exist no canine behavioural studies that would have 
utilized a metabolomics approach. In contrast, the use of metabolomics in human and rodent 
studies is nowadays highly common, and schizophrenia and type D personality in humans, 
and anxiety-related behaviour in rodents, amongst others, have been investigated by 
metabolomics approaches (Altmaier et al., 2013; Filiou et al., 2011; Filiou et al., 2014; 
Prabakaran et al., 2004; Zhang et al., 2011). 
 
 
2.4.2 An overview of common analytical methods used in non-targeted metabolomics  
There are several techniques by which a non-targeted metabolomics study can be performed. 
The most common choices are either nuclear magnetic resonance (NMR), or mass 
spectrometry (MS) coupled with different kind of chromatographic techniques, of which gas 
chromatography (GC) and liquid chromatography (LC) are the most common methods of 
choice, but also capillary electrophoresis (CE) is sometimes applied (Dunn et al., 2013). In 
addition to the choices in metabolite separation methods, there are also several mass 
spectrometers with distinct properties. The ion sources and mass analyzers used are chosen 
according to the aim of the study, and the chemical properties of analytical samples and 
metabolites.  
GC and LC are chromatographic separation methods, which are widely combined with MS in 
metabolomics studies (Wilson, 2010). The biggest difference between GC and LC is the 
composition of the mobile phase: In LC the mobile phase consists of liquid, usually water 
combined with acetonitrile or methanol, and is thus used for analysis of soluble metabolites, 
whereas the mobile phase used in GC consists of an inert gas, such as nitrogen, helium or 
argon, and therefore enables the analysis of volatile compounds. There are also differences in 
the stationary phases between these two methods, but generally the operational principles are 
similar. CE is an electrokinetic separation method in which the electrically charged 
compounds, or ions, are separated according to their mobility under the influence of an 
electric field in a capillary filled with electrolyte solution (Walker, 2010). Due to lower 
repeatability of CE-MS experiments, GC and LC combined with MS are the most commonly 
applied techniques in metabolomics studies (Dunn et al., 2013). 
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NMR spectroscopy is a non-destructive and powerful, qualitative and quantitative analytical 
method applied in metabolomics studies (Hofmann, 2010; Smolinska et al., 2012).  It is based 
on nuclear magnetic resonance, a phenomena in which nuclei absorb and re-emit 
electromagnetic radiation under the influence of a magnetic field, providing information about 
the structure of molecules. Thus it is a good choice for untargeted metabolite profiling studies. 
Even though NMR, GC-MS and LC-MS are all good and effective techniques, particularly 
LC-MS has become one of the most popular choices due to its sensitivity and capability to 
detect a great variety of molecules with varying chemical properties at much lower 
concentrations than possible with NMR (Bowen and Northen, 2010; Theodoridis et al., 2012; 
Xiao et al., 2012; Zhou et al., 2012). It also reduces complexity of samples and allows 
metabolite separation through different kinds of chromatographic methods, such as reversed-
phase liquid chromatography (RPLC) and hydrophilic interaction liquid chromatography 
(HILIC) (Theodoridis et al., 2012; Xiao et al., 2012; Zhou et al., 2012). The possibility to 
utilize different separation methods increases the metabolome coverage, since one separation 
technique is not optimal for all metabolite classes in the sample. For example, HILIC is used 
for separation of hydrophilic compounds including sugars and amino acids, whereas RPLC is 
better for separating hydrophobic compounds, such as lipids. This is due to the different 
chemical properties of these chromatographic methods, and due to the chemical interactions 
between the columns and sample molecules.  
Likewise the choice of separation method affects the number and nature of the compounds 
detected, also ion source and mass analyzer of a mass spectrometry have an impact on the 
metabolite profile obtained. The role of ion source is to convert molecules in the samples into 
ions, which are then measured by mass analyzer according to their mass-to-charge values 
(m/z) (Zhou et al., 2012). In metabolomics studies, the primary choices of ionization methods 
are electrospray ionization (ESI) and electron ionization (EI), and they are typically coupled 
with LC-MS and GC-MS, respectively (Bowen and Northen, 2010; Dunn et al., 2013; Zhou et 
al., 2012). ESI can also be coupled with CE-MS (Bowen and Northen, 2010). The advantage 
of EI is its capability to ionize and dissolve volatile molecules into fragments, whereas ESI is 
described as soft ionization technique, being particularly suitable for untargeted 
metabolomics, since ESI forms intact molecular ions facilitating the identification process 
(Zhou et al., 2012). Thus, the LC-ESI-MS has become the method of a choice in the field of 
non-targeted metabolomics studies.  
The role of mass analyzer is to measure ions by their m/z values, and quadrupoles (Q), time-
of-flight (TOF) instruments, ion traps, and Orbitraps are examples of mass analyzers utilized 
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in LC-MS based untargeted metabolomics experiments (Theodoridis et al., 2012; Zhou et al., 
2012). Among these, TOF analyzer is clearly the instrument of choice due to its high 
sensitivity and mass accuracy (typically < 5 ppm). In order to obtain MS/MS fragmentation 
spectrums, essential for the identification of detected metabolites, tandem mass spectrometers 
consisting of two mass analyzers with a collision cell between them are applied (Aitken, 
2010). Most commonly used combinations are quadrupole TOF (qTOF) and triple quadrupole 
(QqQ). In the case of qTOF instrument, the first mass analyzer, quadrupole analyzer, works as 
a filter letting pass through only those ions with a specific m/z value. These selected ions, 
called as molecular ions or parent ions, are then subjected into the collision cell, where the 
ions collide with the collision gas. This process is called as collision-induced dissociation, and 
it aims to produce fragment ions, also called as daughter or product ions (Zhou et al., 2012). 
These molecular ions and product ions are then subjected into the second mass analyzer, TOF 
analyzer, which separates them according to their m/z values. Finally, the detector measures 
the abundances of the ions, and converts them into signals processed by computer (Aitken, 
2010).   
  
2.4.3 Metabolite identification – the bottleneck of non-targeted metabolomics  
Today the metabolites are identified based on m/z values, retention times and fragmentation 
patterns of compounds in LC-MS based non-targeted studies (Zhou et al., 2012). Since 
molecules with different molecular and elemental formulas may have same m/z values, the 
identification solely based on RTs and m/z values is practically impossible. Thus MS/MS 
fragmentation spectrums provided by tandem mass spectrometry (MS/MS) are indispensable 
for metabolite identification, since these spectrums offer specific information about the 
structure of the compound. This enables the discrimination of metabolites with same 
elemental formula, since they may have unique fragmentation patterns. 
However, there are major challenges in metabolite identification in non-targeted 
metabolomics studies due to the complexity of biological samples as they can contain 
enormous amounts of different metabolites with various chemical and physiological 
diversities (Bowen and Northen, 2010; Dunn et al., 2013). Only a very small proportion of 
these detected metabolites are already known, whereas there are incredibly high numbers of 
uncharacterized compounds that do not have any hits in the databases, or there is a huge lack 
of MS/MS fragmentation data needed for the identification. Moreover, the identification 
process is still mostly performed by manual inspection, and thus it is highly time consuming.  
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These flaws in the metabolite identification process cause a significant bottleneck in non-
targeted metabolomics workflow, since the identification of unknown compounds is 
expensive and time consuming while authentic standards or NMR studies are often required 
(Dunn et al., 2013; Zhou et al., 2012). Due to these major challenges, The Chemical Analysis 
Working Group (CAWG) of the Metabolomics Standards Initiative (MSI) has defined the 
four states of metabolite identification, which are represented in Table 2 (Sumner et al., 
2007). These definitions are made to facilitate and standardize the reporting of metabolite 
identification from metabolomics experiments. In addition to those actions of MSI, it would 
be highly necessary to aggregate all the data from metabolomics studies into one public 
database in order to facilitate and speed up the metabolite identification in the future. Apart 
from m/z values, RTs and MS/MS fragmentation spectrums, it would also be important to 
report about the experimental conditions applied, since they have a major influence on the 
previously mentioned properties of metabolites. This would facilitate the comparison between 
experimental data and data found in the databases.    
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Table 2. The four levels of metabolite identification defined by Metabolomics Standards 
Initiative (MSI) (Sumner et al., 2007). 
Level of 
identification 
Confidence of identification Standards of identification 
1 Definitely identified 
compounds 
Two or more orthogonal and independent properties 
(e.g. retention time and mass spectrum or accurate 
mass and tandem MS) of an authentic chemical 
standard analysed under identical experimental 
conditions are compared with the metabolite of 
interest. 
2 Putatively annotated 
compounds 
Based upon for example spectral similarity with 
public/commercial spectral databases and /or 
physicochemical properties without authentic, 
chemical reference standards.  
3 Putatively characterized 
compound classes 
Based upon for example characteristic 
physicochemical properties of a chemical class of 
compounds, or by spectral similarity to known 
compounds of a specific chemical class.  
4 Unknown compounds Although unidentified or unclassified, these 
metabolites can still be differentiated and quantified 
upon spectral data.  
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3 AIMS OF THE STUDY  
The biological backgrounds of canine anxiety-related conditions, such as fearfulness and 
noise phobia are unknown, and there is an urgent need for unravelling the genes and 
molecules involved in the pathogenesis of anxiety disorders. Professor Lohi’s research group 
has established one of the largest dog DNA banks in the world and significant resources to 
investigate the genetic and environmental correlates of canine anxiety. As a part of the larger 
anxiety program, the aim of this study was to setup a pilot metabolomics study in anxious and 
non-anxious dogs in order to investigate possible differences in the metabolite profiles 
between the case and control groups, and to identify candidate biomarkers for further 
validation studies. The main hypothesis is that the metabolite profile of the anxious dogs 
differs and a biomarker could be discovered for diagnostics and/or prognostics purposes.  
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4 MATERIALS AND METHODS  
4.1 Animals and study design 
This study was part of the research of Prof. Lohi group focusing on anxiety in dogs. All 
material was based on the collections in his laboratory in the University of Helsinki and 
Folkhälsan Research Center. In this study, metabolite profile of the dog was generated by a 
non-targeted LC-qTOF-MS-metabolomics approach, which was performed in the 
Metabolomics Center at Biocenter Kuopio (University of Eastern Finland, School of 
Pharmacy and Department of Clinical Nutrition). Prof. Lohi’s research group has collected 
whole blood samples for the study from anxious and non-anxious pet dogs, who were selected 
based on the previous phenotyping analyses including owner-completed questionnaire (Dog 
behaviour questionnaire, 
https://elomake.helsinki.fi/lomakkeet/16515/lomake.html?rinnakkaislomake=fear), which 
included questions not only about dog’s general behaviour and fearful reactions, but also 
about dog’s puppy period, home environment and daily routines. Ten dogs without any 
history of fear toward people, other dogs or situations, or loud noises were selected to control 
group. Case dogs (N=10) included dogs that show variable fear reactions only against a 
stranger or more generally toward humans, dogs, situations and noises. All the dogs in this 
study were Great Danes, and the dogs were paired between case and control groups by the age 
of blood sampling and sexes.  
 
4.2 LC-qTOF-MS-analysis  
The non-targeted LC-qTOF-MS-analysis and preprocessing of raw data were performed in 
the Metabolomics Center at Biocenter Kuopio (University of Eastern Finland, School of 
Pharmacy and Department of Clinical Nutrition). The common workflow of this type non-
targeted metabolomics study is presented in Figure 3.  
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Figure 3. An overview of the general workflow of LC-qTOF-MS based non-targeted 
metabolomics. The workflow includes sample collection and preparation, LC-MS analysis, and data 
analysis that consists of pre-processing of the raw data, statistical analysis and finally metabolite 
identification. Sometimes targeted structural LC-MS analysis is needed to confirm the identity of 
unknown metabolite.  
 
The first step in LC-MS based non-targeted metabolomics analysis is metabolite extraction. It 
is a highly crucial and challenging step since the chemical properties of metabolites highly 
differ from each other, and due to that, the extraction protocol may have a huge impact on the 
detected final metabolite profile (Theodoridis et al., 2012; Zhou et al., 2012). In present study, 
the extraction of metabolites from the whole blood samples of dogs was conducted as follows: 
400 µL of acetonitrile was added to an aliquot of the collected whole blood sample, 100 µL, 
and mixed in vortex at maximum speed 15 s. The samples were incubated on ice bath for 15 
min, and centrifuged at 16 000 × g for 10 min in order to collect the supernatant. The 
supernatants were filtered into HPLC vials using 0.2 μm Acrodisc® Syringe Filters with a 
PTFE membrane (PALL Corporation, Ann Arbor, MI) prior subjecting to the LC-MS 
analyses. From every whole blood sample, aliquots of 10 µL were taken and mixed together 
in one tube, and used as the quality control (QC) sample in the analysis.  
 
The whole blood samples were analysed by the UHPLC-qTOF-MS system (Agilent 
Technologies 1290 LC system, A Jetstream electrospray ionization (ESI) source, 6540 MS) 
using two different chromatographic techniques, i.e. RP and HILIC, to ensure a maximum 
Sample collection and preparation
metabolite extraction
Liquid chromatography
HILIC and RP
Mass spectrometry
qTOF with both ESI(-) and ESI(+) ionization modes
Data analysis
Data preprocess Statistical 
analysis
Metabolite 
identification
Targeted structural LC-MS analysis
if needed
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metabolome coverage as discussed in the chapter 2.4.2. During this separation step, the 
sample is dissolved in the liquid mobile phase, and the molecules in the sample solution 
interact with immobilised stationary phase with varying strengths, and thus are eluted out of 
the column at different times (retention time, RT) (Wilson, 2010). In present study, the RP 
chromatography was performed on Zorbax Eclipse XDB-C18 column (100 mm × 2.1 mm, 1.8 
µm, Agilent Technologies, Palo Alto, CA, USA). The temperature of the column was kept on 
50°C, and the flow rates of mobile phases were set as 0.4 mL/min. The mobile phases 
consisted of water (eluent A) and methanol (eluent B), both containing 0.01 % (v/v) of formic 
acid. The gradient profile employed was as follows: 2% →100% B (0-10 min); 100% B (10-
14.5 min); 100%→2% B (14.5-14.51); 2% B (14.51-16.50). The injection volume in RP was 
2 µl. The HILIC chromatography was performed on Acquity UPLC BEH Amide column (100 
mm × 2.1 mm, 1.7 µm; Waters Corporation, Milford, MA), and the temperature of the column 
was kept on 45°C . The flow rate was 0.6 mL/min, and eluents A and B consisted of 50% v/v 
and 90% v/v ACN, respectively, both containing 20 mM ammonium formate. The gradient 
was as follows: 100% B (0-2.5 min); 100%→0% B (2.5-10 min); 0%→100% B (10-10.01 
min); 100% B (10.01-12.5 min). The injection volume in HILIC was 2 µl.   
 
Separated and eluted compounds are then injected into the mass spectrometer consisting of 
ion source, mass analyzer and detector (Aitken, 2010; Zhou et al., 2012). It is highly 
recommended to use both positive (+ve) and negative (-ve) ionisation modes to improve the 
metabolome coverage since only one choice of ionisation mode cannot cover all metabolites 
in the samples (Theodoridis et al., 2012; Zhou et al., 2012). In present study, the MS ion 
source conditions were as follows: ESI source, operated both in positive (+ve) and negative (-
ve) ionization mode, drying gas temperature 325°C with a flow of 10 L/min, sheath gas 
temperature 350°C and flow 11 L/min, nebulizer pressure 45 psi, capillary voltage 3500 V, 
nozzle voltage 1000 V, fragmentor voltage 100 V, and skimmer 45 V. For data acquisition, 
the mass range was 20-1600 amu with acquisition rate 1.67 spectra/s. In order to obtain the 
automatic MS/MS spectrums, four ions with the highest intensities were selected from every 
precursor scan cycle for fragmentation performed on the QC samples. After two product ion 
spectra, these ions were excluded, and released again for fragmentation after a 0.25-min hold. 
The collision energies were 10, 20 and 40 V. In the targeted MS/MS analysis, the 
fragmentations were conducted with collision energies of 10 V and 20 V. A continuous mass 
axis calibration was performed by monitoring two reference ions from an infusion solution 
throughout the runs. In positive mode the reference ions were m/z 121.050873 and m/z 
922.009798, and in negative mode m/z 112.985587 and m/z 966.000725. Data acquisition was 
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conducted with MassHunter Acquisition B.04.00 (Agilent Technologies). The QC samples 
were injected in the beginning and ending of the analysis and also after every 10 samples (in 
the middle of run), in order to be able to evaluate the quality of the experiment.  
 
4.3 Collection and preprocessing of the LC-MS data 
The LC-MS data was collected using the vendor’s software MassHunter Qualitative Analysis 
B.05.00 (Agilent Technologies), and the ions were extracted to compounds. The data were 
output as compound exchange format (.cef-files) into the Mass Profiler Professional software 
(MPP 2.2, Agilent Technologies) for compound alignment and data preprocessing, including, 
for example, peak matching and retention time alignment. The data was also cleaned up of 
entities that appeared in only one sample. The aim of the data collection and preprocessing 
was to convert the raw data into a peak list, which can then be more easily interpreted and 
inspected, and exported to some widely available programs, such as Microsoft Excel for 
further statistical evaluation. 
 
4.4 Statistical analysis 
Statistical analysis (Student’s t-test) performed by the MPP software, resulted in four peak 
lists (HILIC ESI(+), HILIC ESI(-), RP ESI(+), and RP ESI(-)) which contained p-values and 
fold changes for every detected compound. The Student’s t-test was used to compare the two 
test groups, and thus find the significantly altered metabolites between the case and control 
groups. Finally, the peak lists were exported to Excel for further data evaluation. The MPP 
software was also used to conduct chemometrics analysis by principal component analysis 
(PCA).  
The Excel files of peak lists were filtered according to p-value < 0.05 and fold change (FC) ≥ 
±1.5, which were considered as statistically significant, in order to reduce the number of 
features to contain only those peaks significantly changed between control and case group. 
The fold change cut-off value was set such high as ±1.5 because the relatively small sample 
size of this pilot study. The occurrence of compounds was also taken into account in order to 
reduce insignificant compounds from data, so that if the compound had p-value < 0.05 and FC 
≥ ±1.5, but it was present only in few replicates in either groups, it was not included in the 
identification state.  
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Finally, the remaining peaks in the lists were manually inspected in the raw LC-MS 
chromatograms and spectra with the Mass Hunter software to check if there were any 
integration mistakes, peaks with really bad quality or molecular ions with really poor 
fragmentation. These kinds of features were filtered out from further analysis. Peak lists were 
also looked through to ensure that the molecular ion of a compound was included into 
automatic MS/MS fragmentation. If not, targeted MS/MS analysis was performed in order to 
obtain the MS/MS fragmentation spectrums of these particular compounds.  
 
4.5 Metabolite identification  
Only those metabolites that were significantly changed between case and control group were 
subjected for manual identification process. The identification was based on the mass-to-
charge (m/z) values of compounds, and on the automatic MS/MS fragmentation spectrums of 
compounds collected during the non-targeted analysis or within targeted MS/MS analysis for 
extracted ions. The MS/MS fragmentation spectrums of the metabolites were compared with 
mass based candidate compounds found in public databases, such as The METLIN Metabolite 
Database (http://metlin.scripps.edu/index.php), Human Metabolome Database (HMDB, 
http://www.hmdb.ca/), and LipidMaps (http://www.lipidmaps.org/), or with fragmentation 
patterns reported in earlier publications. The identification of lipids was based on the MS/MS 
fragmentation, since especially phospholipids, such as phosphatidylcholines (PC), 
lysophosphatidylcholines (LysoPC) and phosphatidylethanolamines (PE) have characteristic 
fragmentation patterns reported in earlier publications (Murphy and Axelsen, 2011; Xia and 
Jemal, 2009; Xu et al., 2009). The inspection of the auto MS/MS or targeted MS/MS 
spectrums of detected compounds was performed using MassHunter Qualitative Analysis 
B.06.00 software (Agilent Technologies, USA), and the matching of MS/MS fragmentations 
was performed manually.   
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5 RESULTS  
5.1 Identification of metabolites significantly altered between anxious and non-
anxious dogs 
A non-targeted metabolite profiling of canine whole blood was conducted in order to evaluate 
the possible differences in the metabolite compositions of anxious and non-anxious dogs. The 
LC-qTOF-MS analysis produced 6 932 features in total from four separate analytical runs 
(986 in HILIC ESI(+), 1 071 in HILIC ESI(-), 3 790 in RP ESI(+), and 1 085 in RP ESI(-)), 
and after statistical evaluation the number of features was reduced to 165 entities (28 in 
HILIC ESI(+), 30 in HILIC ESI(-), 85 in RP ESI(+), and 22 in RP ESI(-)). P-values < 0.05 
and fold changes (FC) ≥ ±1.5 were considered as statistically significant. This final set of 
detected compounds was manually thoroughly scrutinized, and peaks with insufficient 
quality, molecular ions with poor fragmentation, or entities with clear integration mistakes 
were excluded from the final identification step. The final identification resulted in a set of 14 
putatively identified metabolites, and one unknown but statistically highly significant feature 
(Table 3). Also six other statistically significant metabolites, four lipids and two other 
molecules were identified but they were not considered as reliable markers due to their poor 
fragmentations or elution profiles. 
The identification of the significantly altered metabolites was based on the auto MS/MS 
spectrums or targeted MS/MS data for extracted ions. The MS/MS fragmentations spectrums 
were compared mostly against METLIN, but also Human Metabolome Database, LipidMaps, 
and some earlier publications were used. In this chapter, the identification process of detected 
metabolites is divided into two categories: Identification of lipids and identification of 
molecules belogning to other molecule classes. This division is based on different 
identification processes between these two categories, since lipids are mostly identified based 
on their characteristic fragmentation patterns, whereas the identification of other types of 
metabolites is usually based on comparison against MS/MS fragmentation spectrums of 
candidate metabolites in databases. The metabolites identified in this study, and the most 
important information about them, including m/z values, retention times, p-values, fold 
changes and MS/MS fragmentations, is summarized in Table 3, and the principles of their 
identification are discussed more closer in the next sections. 
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Table 3. MS/MS spectral characteristics with p-values, fold changes, and identification references for the putatively identified marker metabolites 
and the most significant non-identified marker metabolites. 
Column 
Ionization 
mode 
Mass m/z 
Retention 
Time 
(min) (RT) 
Putative annotation 
p-value 
* 
fold 
change 
(FC) ** 
CID MS/MS fragmentation 
Identification reference 
# 
HILIC ESI- 189.994 188.986 0.69 Pyrocatechol sulfate  0.015 2.3602 40eV 
108.024, 79.957, 53.042, 80.965, 
109.027 
Pyrocatechol standard 
RP ESI+ 176.095 177.102 1.41 
Unknown metabolite, possibly 
serotonin  
0.0106 1.6718 20eV 
160.074, 71.374, 159.067, 
132.083, 116.127 
MID 74 
HILIC ESI+ 246.137 247.144 1.42 Hypaphorine 0.0485 2.1722 10eV 
188.071, 60.081, 146.061, 
55.017, 247.206, 144.079, 
85.0245, 118.928 
Keller et al. 2013 
HILIC ESI+ 136.039 137.046 1.43 Hypoxanthine 0.025 1.8662 20eV 
137.046, 119.035, 94.040, 
110.035, 55.029, 82.038 
MID 83 
HILIC ESI- 88.016 87.009 1.77 
Unknown metabolite, possibly 
pyruvate 
0.0427 -2.5792  10eV  44.999, 73.857 MID 117 
RP ESI+ 204.09 205.097 2.30 Tryptophan 4.22E-04 -1.5799  10eV 
188.070, 146.060, 144.081, 
130.061, 132.079, 159. 088, 
205.095 
Standard 
RP ESI- 213.009 212.002 2.43 Indoxylsulfuric acid 0.048 1.7765  10eV 212.007, 80.966, 132.043 MID 253 
RP ESI+ 315.277 316.285 8.7 
Putative sphingosine, either 
dehydrophytosphingosine, 6-
hydroxysphingosine, or 
(4OH,8Z,t18:1) sphingosine 
0.0087 1.5028 40eV 
93.071, 43.055, 57.069, 81.070, 
69.069, 67.055, 95.048, 77.040 
MID 392 
RP ESI- 579.319 578.312 8.79 Unknown LysoPC  0.0103 -2.7867 20eV 
293.209, 578.310, 518.291; ESI(+) 
20eV: 104.107, 534.319, 184.074 
MS/MS 
RP ESI+ 517.316 518.323 8.81 LysoPC(18:3) 0.0472 -1.8573 40eV 
184.072, 104.104, 86.094, 
60.082; ESI(-) 20eV: 502.295, 
277.216 
MS/MS 
RP ESI+ 537.295 538.309 10.25 LysoPC(19:0)  0.0488 -1.5329 20eV 
104.106, 501.236, 560.310 
[M+Na]⁺; ESI(-) 20eV: 522.323, 
297.245 
MS/MS 
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RP ESI+ 821.577 822.584 10.67 PC(16:0/23:5) 0.0017 -2.0557  20eV 
822.584, 184.074; ESI(-) 40 eV: 
806.556, 343.249, 255.233 
MS/MS 
RP ESI+ 311.319 312.326 11.01 Unknown metabolite 0.024 2.8456 20eV 
312.326, 57.071, 102.095, 
100.075, 214.214, 81.068 
 - 
RP ESI+ 801.587 802.595 11.35 PC(18:0/19:1) 0.0376 -1.975 20eV 
184.072, 784.583, 802.594; ESI(-) 
40eV: 295.229, 283.261 , 786.565 
MS/MS 
RP ESI+ 803.545 804.554 11.74 PC(20:5/18:2) 0.0393 2.7507 10eV 
804.550, 184.074, 86.095; ESI(-) 
40eV: 44.998, 301.223, 279.231 
MS/MS 
RP ESI- 749.54 748.531 12.51 PE(P-18:1/20:4) 0.0447 1.8087 20eV 
784.526, 303.234; ESI(+) 20eV: 
361.275, 390.277, 609.529, 
750.551 
MS/MS 
RP ESI+ 809.592 810.599 12.64 PC(18:0/20:4) 0.0200 -1.9963 40eV 
184.073, 86.095; ESI(-) 40eV: 
303.234, 283.265 , 794.567 
MS/MS 
* P-values < 0.05 were considered as statistically significant. 
** Fold changes ≥ 1.5 were considered as statistically significant. Positive values indicate increased whole blood levels in case dogs vs. control dogs, whereas negative values indicate 
decreased whole blood levels in case dogs vs. control dogs.  
# Identification of metabolites is based on manual MS/MS spectral interpretation, METLIN ID when MS/MS spectrum available, commercial standard compound, or some earlier published 
fragmentation patterns.  Keller et al., 2013, Hypaphorine is present inhuman milk in association with consumption of legumes. J. Agric. Food Chem. 61:7654–766
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5.2 Identification of other metabolites than lipids detected in canine whole blood  
Although a major proportion of the identified metabolites were lipids, there were a few other 
metabolites also (Table 3). The first step in the identification process is the evaluation of the 
quality of the peak, since it provides necessary information about the success of analytical 
steps, such as chromatographic separation and efficient ionization. High and well-defined 
peak tells that the compound is properly separated, and thus it can be considered as a mark of 
reliable compound. Figure 4A presents an extracted ion chromatogram of metabolite 
identified as hypoxanthine, and as can be seen, the peak is high and sharp, and thus has great 
quality. The HILIC ESI(+) MS/MS fragmentation spectra of the experimental compound 
shows a molecular ion at m/z 137.046, and intense fragment ions at m/z 55.029, m/z 82.038, 
m/z 94.040, m/z 110.035, and m/z 119.035 (Fig. 4B). A comparison with spectrum of 
hypoxanthine in METLIN (Fig. 4C) indicates that the metabolite detected in our experiment is 
hypoxanthine, since the fragmentation pattern of hypoxanthine (fragment ions at m/z 55.030, 
m/z 82.041, m/z 94.040, m/z 110.035, and m/z 119.035) is identical to the MS/MS 
fragmentation spectrum observed in our experiment. The whole blood levels of this particular 
metabolite were increased among anxious dogs (fold change 1.8662, p-value 0.025) when 
compared with non-anxious dogs.  
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Figure 4. An extracted ion chromatogram of an experimental metabolite, and a comparison of 
MS/MS fragmentation of the experimental metabolite with spectrum of hypoxanthine from 
METLIN. A: An extracted ion chromatogram of an experimental metabolite shows that the quality 
and elution profile of the peak are both excellent. B: The MS/MS fragmentation spectrum of feature 
with m/z value 137.046 and retention time 1.43 in the HILIC ESI(+) mode. The MS/MS fragmentation 
shows peaks at m/z 55.029, m/z 82.038, m/z 94.040, m/z 110.035, and m/z 119.035. C: A spectrum of 
hypoxanthine in METLIN database (METLIN ID 83) with intense fragment ions at m/z 55.030, m/z 
82.041, m/z 94.040, m/z 110.035, m/z 119.035, and a molecular ion at m/z 137.046. As can be seen, the 
fragmentation of our experimental compound is identical with hypoxanthine, and thus this metabolite 
can be putatively identified as hypoxanthine.   
C 
B 
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Metabolites with m/z 188.986 (HILIC ESI(-) analysis), m/z 247.144 (HILIC ESI(+) analysis),  
m/z  212.002 (RP ESI(-) analysis), and  m/z  205.097 (RP ESI(+) analysis) were detected, and 
putatively identified as pyrocatechol sulfate, hypaphorine, indoxylsulfuric acid and 
tryptophan, respectively. The identification of pyrocatechol sulfate was based on MS/MS 
fragmentation spectrum comparison with pyrocatechol standard, since the metabolite formed 
MS/MS fragment ions at m/z 53.034, m/z 108.024 and m/z 109.027, which are also visible in 
the MS/MS spectrum of the pyrocatechol standard. The MS/MS fragmentation spectra of the 
compound show also an intense fragment ion at m/z 79.957 which corresponds to the sulfate 
group [SO3]
- in the structure of pyrocatechol sulfate. The difference in the levels of this 
compound between the two test groups was relatively high, since the fold change was 2.3602 
(p-value 0.015), indicating a significant increase among anxious dogs. Hypaphorine was 
identified based on earlier published MS/MS fragmentation spectrum conducted by Keller 
and colleagues (Keller et al., 2013). The MS/MS fragmentation of the metabolite shows same 
fragment ions at m/z 188.071, m/z 146.061, m/z 144.079, and m/z 118.928 as does the MS/MS 
spectrum conducted by Keller et al. (2013), although there is differences in the intensities of 
the peaks, which may result from a slightly different analytical conditions. The whole blood 
levels of hypaphorine were found to be increased in case group (fold change 2.1722, p-value 
0.0485). The metabolite with m/z 212.002 formed MS/MS fragment ions at m/z 132.043 and 
m/z 80.966, and was thereby identified as indoxylsulfuric acid based on the same fragments in 
the MS/MS spectrum of indoxylsulfuric acid in METLIN (MID 253). Case dogs had 
increased levels of this particular metabolite when compared with control dogs (fold change 
1.7765, p-value 0.048). The MS/MS fragmentation spectrum of metabolite with m/z 205.097 
is identical with the MS/MS fragmentation of tryptophan standard, having the same fragment 
ions at m/z 188.070, m/z 159. 088, and m/z 146.060, and thus this metabolite can be identified 
as tryptophan (Fig. 5). The whole blood levels of tryptophan are decreased in case group (fold 
change -1.5799, p-value 4.22E-04) The same metabolite is found as a marker also in RP ESI(-
) analysis, but the elution profile of tryptophan is poor and unclear in there. However, due to 
the fact that tryptophan was not found as a marker in HILIC analyses, the significance of this 
finding may be questionable since HILIC is more reliable chromatographic method for 
detection of amino acids than RP.  
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Figure 5. A comparison of MS/MS fragmentation spectrum of metabolite with m/z 205.0971 with 
tryptophan standard. A: The MS/MS fragmentation of metabolite with m/z 205.097 and RT 2.30 in 
RP ESI(+) analysis shows intense fragment ions at m/z 188.070 and m/z 146.060. B: The MS/MS 
fragmentation spectrum of tryptophan standard shows identical fragmentation pattern with the 
experimental compound with m/z 205.097, and thus this compound is identified as tryptophan.  
In addition to these four putatively identified metabolites, there were two other significantly 
altered features between anxious and non-anxious dogs, but the identifications of these 
compounds are unclear due to poor MS/MS fragmentations or elution profiles. These 
metabolites with m/z 177.102 and RT 1.41 (RP ESI(+) analysis), and m/z 87.009 and RT 1.77 
(HILIC ESI(-) analysis), could be identified as serotonin and pyruvate, but these 
identifications should be considered with great caution. The compound with m/z 177.102 
would match up with serotonin by its mass, but the MS/MS fragmentation spectra of this 
compound slightly differs from the MS/MS spectra of serotonin in METLIN (MID 74), since 
there is formed an intense fragment ion at m/z 71.374 that is not visible in the spectrum of 
serotonin in METLIN. Otherwise, however, the MS/MS fragmentation of the metabolite is 
identical with serotonin, showing fragment ions at m/z 160.074, m/z 159.067, m/z 132.083, 
and m/z 116.127. The level of this compound was slightly increased in anxious dogs’ blood 
A 
B 
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when compared with control dogs (fold change 1.6718, p-value 0.016). The MS/MS 
fragmentation spectrum of m/z 87.009 is poor, and it did not match up with the spectra of 
pyruvate (MID 117), although the compound had same mass than pyruvate. The most intense 
fragment ions of this particular compound were m/z 44.999 and m/z 73.857. The mass of this 
feature would have matched up with a couple of other molecules too in METLIN, but their 
spectrums were not compatible with the spectrum of the compound. The fact that the MS/MS 
spectrum was fairly poor may be due to non-optimal analytical conditions, and thus the 
quality of the spectrum may be improved by analytical optimizing. However, it is unclear if 
this significantly decreased metabolite among case group (fold change -2.5792, p-value 
0.0427) really is pyruvate.  
Finally, there was also found a compound with m/z 312.326 and retention time 11.01 in the 
RP ESI(+) analysis, but neither the mass nor the m/z value of this feature had any hits in 
METLIN. Due to the unknown mass and unfamiliar MS/MS fragmentation of this metabolite 
it is impossible to say in which molecule class it could belong, neither what the exact identity 
of this compound could be. However, the retention time highly suggest that this feature could 
be fatty acid. Noteworthy, this unidentified metabolite is remarkably significant having a high 
fold change (2.8456), which indicates that anxious dogs have highly increased blood levels of 
this particular molecule compared to non-anxious dogs.  
 
5.3 Identification of lipids detected in canine whole blood 
The major proportion of the significantly altered metabolites between anxious and non-
anxious dogs were identified as lipids, especially phospholipids (Table 3). The MS/MS 
fragmentation is the base of the lipid identification, and there are several earlier publications 
about the characteristic fragmentation patterns of different phospholipid classes, such as 
phosphatidylcholines (PC), lysophosphatidylcholines (LysoPC) and 
phosphatidylethanolamines (PE) (Murphy and Axelsen, 2011; Xia and Jemal, 2009; Xu et al., 
2009). The identification of phospholipids relies on fragmentation data from both positive and 
negative ionization modes: The positive ionization mode reveals the class of the phospholipid, 
since it yields information about the polar head group of the lipid, whereas the negative 
ionization mode is informative in order to reveal the lipid’s fatty acid composition (Murphy 
and Axelsen, 2011; Xia and Jemal, 2009). For PCs and LysoPCs, the most characteristic 
diagnostic feature is the protonated head group at m/z 184.07, whereas PEs can be 
distinguished from other classes of phospholipids by a positive neutral loss scan of 141 Da 
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([M-140]+), and negative precursor ion scan of m/z 196. The fatty acid composition of the 
phospholipids can be verified by the fragmentation in the negative ionization mode, since the 
deprotonated fatty acid chains present on the glycerol backbone of the lipids are visible there. 
Most of the phospholipids, including PEs, are as deprotonated molecular ions ([M-H]-) in the 
negative ionization mode except PCs and LysoPCs, which are found as formate adducts 
([M+45]-) in the presence of formate buffer. Due to this, formate adducts of PCs and LysoPCs 
show a characteristic neutral loss scan of 60 Da in the negative ionization mode.  
In Figure 6, an extracted ion chromatogram (A), and MS/MS fragmentations in the RP ESI(+) 
(B) and ESI(-) (C) analysis of a metabolite identified as PC(18:0/19:1) are presented as an 
example of the identification process of PCs. Most of the lipids detected in this experiment 
had very poor elution profiles and qualities of peaks, but this lipid was a rare exception 
having elution profile of moderate quality (Fig. 6A). As described previously, the 
identification of PCs is based on the presence of the phosphocholine head group at m/z 
184.072 in the positive ionization mode (Fig. 6B), and the neutral loss scan of 60 Da specific 
to formate adducts ([M+45]-) of PCs in the negative ionization mode with m/z 786.565 for this 
compound (Fig. 6C). In the MS/MS fragmentation spectrum in positive mode there is also an 
intense fragment at m/z 784.583, which is due to the loss of water ([M-H2O]
+). In the negative 
ionization spectrum there are fragment ions at m/z 283.261 and m/z 295.229 corresponding to 
stearic acid (C18:0) and C19:1, respectively, and thus it can be verified that this compound is 
PC(18:0/19:1).  
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Figure 6. The chromatogram and MS/MS fragmentation of a metabolite identified as 
PC(18:0/19:1). A: An extracted ion chromatogram of lipid with m/z 802.595 and retention time 11.35. 
B: MS/MS spectrum of the same feature in the RP ESI(+) ionization mode. A fragment ion at m/z 
184.072 is characteristic to the phosphocholine head group. C: MS/MS spectrum of the same feature 
in the RP (ESI-) ionization mode as a formate adduct at m/z 846.588 ([M+45]-). The fragment ions at 
m/z 283.261 and m/z 295.229 correspond to stearic acid (C18:0) and C19:1, respectively. The fragment 
ion at m/z 786.565 corresponds to the neutral loss scan of 60 Da, which is specific for formate adducts 
([M+45]-). Thus, this metabolite was identified as PC(18:0/19:1) based on the fragmentation patterns 
in both two ionization modes.  
 
A 
B 
C 
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The fragmentation of LysoPCs is highly similar with that of PCs, since they both are 
characterized by the fragment ion at m/z 184.07 in the positive ionization mode (Xu et al., 
2009). However, one exception distinguishes these two molecules, and that is a fragment ion 
at m/z 104.10 in the positive ionization mode, which is specific to LysoPCs, and especially for 
sn-1 isomers of LysoPCs. Figure 7 presents MS/MS fragmentations of a metabolite with m/z 
518.323 in the RP ESI(+) (A) and ESI(-) (B) analysis. The fragment ions at m/z 104.104 and 
m/z 184.072 in the positive ionization mode indicate that this compound must be LysoPC 
(Fig. 7A). There is also a fragment ion at m/z 86.094, which results from a further loss of H2O 
from the ion at m/z 104.104. As if PCs, also LysoPCs are visible as formate adducts in the 
negative ionization mode (Fig. 7B). Thus, there is a fragment ion at m/z 502.295 in the 
negative ionization mode, corresponding to the neutral loss of 60 Da of formate adduct. In the 
negative MS/MS fragmentation is also a fragment ion at m/z 277.216 corresponding to α-
linoleic acid (C18:3), and thus this metabolite can be verified as LysoPC(18:3).  
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Figure 7. The MS/MS fragmentation of a metabolite identified as LysoPC(18:3). A: MS/MS 
spectrum of a lipid with m/z value 518.323 and retention time 8.81 in the RP ESI(+) mode. The 
fragment ion at m/z 184.072 is characteristic to the phosphocholine head group, whereas the fragment 
ion at m/z 104.104 is specific to LysoPCs. B: MS/MS spectrum of the same feature in the RP ESI(-) 
mode as a formate adduct at m/z 562.316 ([M+45]-). The fragment ion at m/z 277.216 corresponds to 
α-linoleic acid (C18:3), and the fragment ion at m/z 502.295 corresponds to the neutral loss scan of 60 
Da, which is specific for formate adducts ([M+45]-). Thus, this metabolite was identified as 
LysoPC(18:3) based on the fragmentation patterns in both two ionization modes.  
 
The identification process of other phosphocholines identified in this study (Table 3) is 
identical to the identification of these two above presented lipids, and thus they are not 
described here in detail. Also the identification of PE(P-18:1/20:4) is conducted on the basis of 
the identification principles of PEs discussed earlier in this section. Apart from these 
identifications, there was also found a compound with m/z 578.312 and retention time 8.79 in 
RP ESI(-) analysis, which would match to a LysoPC based on its MS/MS fragmentation 
spectrums in both the positive and negative ionization modes, since there were fragment ions 
at m/z 104.107 and m/z 184.074 in the RP ESI(+) analysis, and a peak m/z 293.209 
A 
B 
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corresponding to C19:2 in the RP ESI(-) analysis. However, this metabolite had no 
appropriate mass based hits in METLIN or LipidMaps that would match with the 
fragmentation of this metabolite. Based on the MS/MS frgamentation, it can be assumed that 
this feature would be LysoPC(19:2), but since the databases were incapable to verify this, the 
level of this identification stays unknown. A feature with m/z value 316.285 and retention 
time 8.7 in the RP ESI(+) analysis was putatively identified as sphingosine, either as 
dehydrophytosphingosine, 6-hydroxysphingosine, or (4OH,8Z,t18:1) sphingosine, based on 
its m/z value. It is impossible to find out the exact structure of this compound due to the lack 
of comparable spectrums of these three putative candidate molecules, but based on the 
comparison with spectrum of sphingosine in METLIN (METLIN ID 392), it can be assumed 
that this metabolite is belonging to sphingosine metabolite family. To acquire a more detailed 
information about identified phospholipids and the putatively identified sphingosine, and their 
MS/MS fragmentations, the reader is recommended to review Table 3.  
In addition to these significantly altered lipids presented in the Table 3, there were detected 
four other statistically significant phosphocholines which cannot be considered as truly 
reliable markers due to the poor quality of their elution profiles. These are compounds with 
m/z 860.598 and RT 10.82, m/z 840.573 and RT 10.96, m/z 798.562 and RT 11.08, and m/z 
842.589 and RT 11.21, identified as PC(18:0/24:7), PC(22:2/18:1), 16:0/12-HETE PC or 
16:0/5-HETE PC, and PC(22:2/18:0), respectively. PC(18:0/24:7) was identified based on its 
fragment ions at m/z 184.074 in the RP ESI(+) analysis, and at m/z 844.569 (neutral loss scan 
of 60 Da of formate adduct) m/z 283.263 (C18:0) and m/z 353.232 (C24:7) in the RP ESI(-) 
analysis. Compound with m/z 840.573 and RT 10.96 had fragment ions at m/z 184.071 in the 
RP ESI(+) analysis, and at m/z 824.574 (neutral loss scan of 60 Da of formate adduct), m/z 
281.249 (C18:1), and m/z 335.222 (C22:2) in the RP ESI(-) analysis, and thus it was 
identified as PC(22:2/18:1). 16:0/12-HETE PC or 16:0/5-HETE PC had fragment ions at m/z 
184.07 in the RP ESI(+) analysis, and at m/z 255.232 and m/z 319.227 in the RP ESI(-) 
analysis, corresponding to palmitic acid (C16:0) and arachidonic acid (C20:4) with a hydroxyl 
group either in carbon atom 5 or 12, respectively. It was impossible to find out the location of 
the hydroxyl group in the structure, and thus an exact identity of this metabolite is unclear. 
PC(22:2/18:0) had fragment ions at m/z 184.074 in the RP ESI(+) analysis, and at m/z 826.562 
(neutral loss scan of 60 Da of formate adduct), m/z 283.262 (C18:0), and m/z 335.221 (C22:2) 
in the RP ESI (-) analysis.  
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Majority of the identified lipids evaluated statistically significant in this study were decreased 
in anxious dogs when compared to non-anxious dogs: all metabolites identified as 
phosphocholines or lysophosphocholines, expect one exception, had negative fold changes 
indicating decreased levels of these particular metabolites in case group. The exception to the 
rule was PC(20:5/18:2), which had positive and relatively high fold change (2.7507) 
indicating an increased concentration of this particular lipid in anxious dogs’ blood. The 
phospholipid identified as PE(P-18:1/20:4) was also increased in the blood of anxious dogs. 
One of the lipids, putatively identified as some sphingosine-like molecule, had positive but 
relatively low fold change value (1.5028) demonstrating a slight difference between case and 
control groups. The p-values and fold changes of all these lipids are presented in Table 3. 
Also metabolites identified as PC(42:7), PC(22:2/18:1), 16:0/12-HETE PC or 16:0/5-HETE 
PC, and PC(22:2/18:0) had all decreased levels in case dogs, but these phosphocholines 
cannot truly be considered as reliable markers because of their poor elution profiles.  
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6 DISCUSSION  
The biological background of canine anxiety is largely unknown and has embarked several 
new studies to identify underlying neuronal pathways. Our research group has previously 
performed clinical, behavioural and genetic studies in canine anxiety but wanted now to 
explore a novel non-targeted metabolomics approach for improved diagnostics and 
understanding of the molecular mechanisms. The aim of this pilot study was to examine the 
possible differences of metabolite profiles between a small cohort of anxious and non-anxious 
dogs, and to identify candidate biomarkers using untargeted metabolite profiling.  
Our results identify several significantly altered metabolites between the two test groups. This 
suggests that the metabolite profile of an anxious dog differs from that of a non-anxious dog.  
Several lipids as well as molecules involved in oxidative stress, inflammation and tryptophan 
metabolism were identified indicating possible alterations in the metabolism of the respective 
pathways, such as oxidative stress and low-grade inflammation, which in turn may cause 
disruptions in tryptophan metabolism. This pilot study demonstrates that the non-targeted 
metabolomics approach may have sufficient sensitivity to identify altered biomarkers in 
canine anxiety. However, there is a need for both analytical optimization and replication in 
larger cohorts of dogs before more mature conclusions.  
Fourteen significantly altered metabolites between the two test groups were identifiable at 
some level, whereas the identity of one highly significant feature remains unknown. Also six 
other statistically significant compounds were identified, but they could not be considered as 
reliable markers due to their poor and unclear elution profiles and/or MS/MS fragmentations. 
Slightly more than half of the identified metabolites were lipids, especially phospholipids, 
with one exception identified as sphingosine. Among phospholipids, the majority were 
phosphatidylcholines (PC), but also two lysophosphatidylcholines (LysoPC) and one 
phosphatidylethanolamine (PE) were detected. This distribution in the lipid composition of 
canine whole blood is in agreement with a previous study that has proved PCs to be the most 
abundant phospholipid class in canine plasma (Maldonado et al., 2001).  
The whole blood levels of detected lipids showed decreasing trend among anxious dogs when 
compared to control group, except for three exceptions, PE(P-18:1/20:4), PC(20:5/18:2) and 
putative sphingosine, which levels were increased among case group. Stearic acid (C18:0), 
arachidonic acid (C20:4) and palmitic acid (C16:0) were the most common fatty acid residues 
in phospholipids in dogs. This is in agreement with the study of Maldonado et al (2001), who 
found that saturated fatty acids (SFAs) C16:0 and C18:0, a monounsaturated fatty acid C18:1, 
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and omega-6 PUFAs C18:2 and C20:4 were the most abundant fatty acids in canine plasma. 
The blood lipid composition of an individual results highly from the nutrition, and a similar 
trend was observed in this study also, since SFAs stearic and palmitic acid that were the most 
abundant fatty acids among dogs, are contained in meat which is the major source of nutrition 
among dogs. However, the fatty acid composition of the phospholipids results from 
endogenous fatty acid/lipid metabolism, and thus could potentially reflect the possibility that 
lipids are involved in some pathological conditions. Indeed, although nutrition may explain 
the frequency of specific fatty acids within dogs, it may not itself explain the observed 
changes in the levels of detected phospholipids between anxious and non-anxious dogs unless 
there would be a significant difference in the lipid constitutions of case and control dogs’ 
diets. The diet profiles for each dog were not available in the study. Thus, the differences 
between the test groups may be a sign of altered fatty acid metabolism, reflecting disturbances 
in the metabolism of lipids in case dogs. Indeed, especially phospholipids may have a 
significant role in the development of some diseases, since they are major components of cell 
membranes, thus having an impact, for example, on the fluidity of cellular membranes and 
homeostasis of the cell, and omega-3 PUFA deficiency has been associated with anxiety-like 
and stress-related behaviour both in humans and mice, for example (Bosch et al., 2007; Carrie 
et al., 2000; DeMar et al., 2006; Hennebelle et al., 2014; Liu et al., 2013; Takeuchi et al., 
2003).  
Oxidative stress is known to be caused by an accumulation of reactive oxygen species (ROS), 
when the balance between pro- and antioxidant systems of the cell is disturbed (Bouayed et 
al., 2009). As a result, several cellular components, such as DNA, lipids, nucleic acids and 
proteins are damaged, and the levels of pro-inflammatory cytokines are increased 
significantly. Thus, oxidative stress is speculated to be involved in several pathological 
conditions, including cancer, diabetes, atherosclerosis, cardio-vascular disorders, and 
autoimmune diseases. Recently, also links between oxidative stress and neuropsychiatric 
disorders like schizophrenia, anxiety, PTSD and social phobia have been implicated both in 
human and mice, and that is not a wonder since the constitution of the brain is highly lipid-
rich, making the brain especially vulnerable to oxidative damage and lipid peroxidation 
(Bouayed et al., 2009; Filiou et al., 2011; Filiou et al., 2014; Prabakaran et al., 2004; Rammal 
et al., 2008; Wilson et al., 2013; Zhang et al., 2011). Notably, anxiety-like behaviour is 
demonstrated to be reduced as a consequence of mitochondria-directed antioxidants, 
providing supporting evidence for the role of oxidative stress in the pathogenesis of anxiety-
related disorders (Stefanova et al., 2010).  
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Results from our data suggest that oxidative stress may also be implicated in canine anxiety, 
since increased levels of oxidative stress related metabolites were detected in the whole blood 
of anxious dogs when compared to non-anxious dogs. Hypoxanthine, a purine metabolite and 
deamination product of adenine, has been observed to stimulate oxidative stress in rats in 
vitro (Mesquita Casagrande et al., 2013; Rodrigues et al., 2014). In our study, fearful and 
anxious dogs had higher whole blood levels of hypoxanthine than dogs without any anxiety or 
fear related behaviour. The oxidative stress promoting effects of hypoxanthine has been 
demonstrated to be mediated by xanthine oxidase (XO), an enzyme which oxidases 
hypoxanthine to xanthine and further to uric acid, and as by-product highly deleterious 
superoxide is generated (Chen et al., 2012). Also indoxylsulfuric acid, a metabolite found to 
be increased in case dogs when comparing to control dogs, is a known promoter of oxidative 
stress (Dou et al., 2007; Muteliefu et al., 2009).  Indoxylsulfuric acid is a metabolite of 
tryptophan and a uremic toxin, and it has been associated with chronic kidney diseases as well 
as it has been observed to increase endothelial ROS production, possibly by activating 
NAD(P)H oxidase, a pro-inflammatory agent, or inhibiting antioxidant glutathione (Dou et 
al., 2007). Moreover, Dou and colleagues (2007) demonstrated that antioxidants N-asetyl-L-
cysteine (NAC) and vitamins E and C have inhibiting effects to the oxidative stress caused by 
indoxylsulfuric acid supporting the suggested pro-oxidant role of indoxylsulfuric acid.  
PE(P-18:1/20:4) is a plasmalogen, a member of a subclass of ether-linked lipids that are 
characterized by an ether linkage at the sn-1 position and an ester-linkage at the sn-2 position 
on the glycerol backbone of the lipid (Wallner and Schmitz, 2011). Plasmalogens are 
suggested to be markers of oxidative stress since they might be endogenous antioxidants 
protecting mammalian cells against the damage caused by ROS, and for example patients 
suffering from sepsis are discovered to have significantly decreased plasma concentrations of 
plasmalogens (Brosche et al., 2013; Wallner and Schmitz, 2011). Our non-targeted 
metabolomics study of anxious and non-anxious dogs’ whole blood detected significantly 
increased levels of a particular plasmalogen, PE(P-18:1/20:4), in case dogs. This effect is 
opposite to that seen in the study of Brosche and colleagues (2013) focusing on the analysis of 
oxidative stress markers in septic patients, and one suggestion is that the increase observed in 
our study may be due to an elevated antioxidant response to increased oxidative stress 
associated with anxiety. It has to be noted that our results only demonstrate that the levels of 
possible oxidative stress markers hypoxanthine, indoxylsulfuric acid and PE(P-18:1/20:4) are 
increased in the whole blood of anxious dogs, and thus they can be regarded only as 
potentially reflecting the level of oxidative stress in the brain. A few recent studies have, 
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however, suggested that also altered plasma levels of molecules related to oxidative stress can 
be implicated in anxiety (Filiou et al., 2014; Wilson et al., 2013). 
 
Our untargeted metabolite profiling of canine whole blood revealed lower levels of 
tryptophan in anxious than non-anxious dogs, although the significance of this finding may be 
questionable since tryptophan was detected in RP analysis and not in HILIC analysis, which 
would be more reliable method for detection of amino acids. Tryptophan is an essential amino 
acid, meaning that it must be received from the diet. In the brain it functions as a precursor of 
serotonin (5-HT), an important neurotransmitter that has been implicated in pathogenesis of 
several behavioural diseases (Kanai et al., 2009; Miura et al., 2011). The plasma 
concentration of tryptophan is an indicator of the brain tryptophan availability, and since the 
tryptophan levels have direct effects to 5-HT levels, it is an indicator of the brain 5-HT 
synthesis too. Thus altered levels of tryptophan result also in altered levels of serotonin, 
which in turn may cause behavioural problems, such as anxiety and depression. Tryptophan is 
metabolized in the body via two major metabolic pathways; kynurenine and 5-HT pathways. 
The kynurenine pathway is initiated by two enzymes, indoleamine 2,3-dioxygenase (IDO) 
and tryptophan 2,3-dioxygenase (TDO), whereas the 5-HT pathway is regulated by 
tryptophan hydroxylase-2 (TPH2). Disruptions in both of these pathways are implicated in the 
pathogenesis of mood disorders, since 5-HT plays a role as mood regulator in the brain, while 
the metabolites of the kynurenine pathway show both neurodegenerative and neuroprotective 
functions, and have been implicated in depression, for example.  
 
One mechanism explaining the lower tryptophan levels of anxious dogs may be differences in 
the diet between case and control groups, since tryptophan has to be received from nutrition. 
Thus low levels of tryptophan or an unfavourable amino acid composition in the diet of case 
dogs may explain these changes. However, there is also evidence that stress and 
immunological challenges, such as inflammation, may disturb the tryptophan metabolism by 
shifting the balance between the two tryptophan metabolic pathways towards kynurenine 
pathway (Kanai et al., 2009; Miura et al., 2011). Indeed, stress-induced glucocorticoids as 
well as pro-inflammatory cytokines are observed to peripherally up-regulate the activity of 
TDO and IDO, resulting in increased catabolism of tryptophan to kynurenine, and thus 
decreased blood levels of tryptophan are measured. Because of low blood concentration of 
tryptophan, its transport to the brain trough the blood-brain barrier is reduced, which in turn 
may result in decrease in the 5-HT synthesis in the brain (Kanai et al., 2009; Miura et al., 
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2011). Same kind of shift from the 5-HT pathway to kynurenine pathway is observed in the 
brain caused by stress or inflammation, similarly resulting in reduced 5-HT synthesis. These 
alterations in the brain 5-HT synthesis and levels are known to be crucial in several 
psychiatric diseases, and significant correlations between plasma levels of kynurenine and the 
severity of anxiety symptoms in humans have been observed (Orlikov et al., 1994). Moreover, 
TDO-/- mice have increased tryptophan levels, and they do not show anxiety-like behaviour 
(Kanai et al., 2009). Recently, associations between low-grade inflammation and both 
depression and anxiety disorders are demonstrated (Dowlati et al., 2010; Liukkonen et al., 
2011; Spitzer et al., 2010; Vogelzangs et al., 2013; Zunszain et al., 2012). These findings 
further support the theory of stress- and pro-inflammatory-induced overactivation of IDO and 
TDO enzymes, leading to increased production of neurotoxic metabolites of the kynurenine 
pathway, and increased anxiety- or depressive-like behaviour. This particular theory is also a 
potential explanation for the observed decrease in the levels of tryptophan in anxious dogs in 
this study. This also supports the finding that anxious dogs may suffer from oxidative stress 
since inflammation and oxidative stress are closely connected to each other.  
 
Hypaphorine (C14H18N2O2), an indole alkaloid and a betaine of tryptophan found in pulses, 
has been observed to induce sleep in mice (Keller et al., 2013; Ozawa et al., 2008). In our 
data, anxious dogs had significantly higher levels of this particular metabolite than dogs 
without any fears or anxieties. Only a little is known about the biological functions of this 
metabolite, and there is no data suggesting a connection between hypaphorine and behaviour. 
Thus it can only be speculated if this particular metabolite could somehow be related to 
pathological anxiety. There is a possibility that the altered levels of hypaphorine between the 
test groups would result from differences in the nutrition of case and control dogs, since 
hypaphorine is a biomarker of consumption of pulses, and thus higher levels of hypaphorine 
in the blood of anxious dogs would be a result of consumption of foods containing greater 
levels of lentils. Unfortunately, the details of the nutrition of the dogs are not known and 
moreover, it is highly unlikely that such a significant and systematic difference between the 
two test groups would result from nutrition solely. Instead, these changes in the hypaphorine 
levels observed in this study may also be explained by its link to tryptophan, since 
hypaphorine is an N-methylated form of tryptophan. Indeed, also the identification of 
tryptophan metabolite indoxylsulfuric acid as marker of anxiety in dogs further supports the 
theory that the tryptophan metabolism of anxious dogs is disturbed, and thus changes in it 
may truly be involved in the pathogenesis of anxiety.  Also altered levels of metabolite 
tentatively identified as serotonin were observed in our study, but these changes cannot be 
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considered reliable due to unclear MS/MS fragmentation and thus uncertain identification of 
this particular metabolite. Moreover, the blood levels of 5-HT may not correlate with the 
brain 5-HT levels since 5-HT is not able to cross the blood-brain barrier, and thus the changed 
blood 5-HT levels observed in this study may not tell anything about the possible disturbances 
in the brain serotonergic system.   
We also observed a few other interesting and significantly altered metabolites between the 
test groups, but which do not have any established relations to anxiety-like behaviour. Thus 
the reasons causing the altered levels of these specific metabolites, such as pyrocatechol 
sulfate, a phenolic compound with molecular formula C6H6O5S, remains unclear and further 
investigation is highly needed to unravel these connections. Also the role of sphingosines in 
anxiety can only be speculated, although they are known to be significant components of 
sphingolipidis, a class of molecules, which form the major proportion of cellular membranes 
and are involved in cell signalling. The identity of the one unknown metabolite detected in 
this study would be highly important to be revealed in order to be able to assess its 
biochemical functions and possible connections with anxiety. Thus, further studies are needed 
to understand the role of these molecules. 
This study had several limitations due to its status as a pilot metabolomics study of anxiety-
related behaviour in dogs. Many of the limitations of this study are involved in the LC-MS 
analysis. First, the sample material used in this study was whole blood and not plasma as 
usual. This may have had a great impact on the metabolite profiles found in here, and also on 
the quality of the data. Second, the LC-MS platform used in here is based on human studies 
since there exist no established platform for non-targeted metabolomics studies in dogs. Thus 
the experimental conditions may not have been optimal for analysis of dogs’ blood samples, 
effecting on the quality of the data and the metabolite profiles observed. Thirdly, among all 
the twenty blood samples, there were four more recently taken blood samples, two in case 
group and two in control group. It can be assumed that this had an influence on the detected 
metabolite profiles of individual dogs, since the metabolite compositions of more recently 
taken blood samples differed slightly from the ones taken previously, and a similar trend was 
present in all these four more recently taken samples. Based on this, it can be concluded that 
the longer storage period has affected to the molecular composition of previously taken blood 
samples.  
It must also be taken into account that the sample size in this study was relatively small, as we 
had only ten anxious and ten non-anxious dogs, and thus the reliability of our results may be 
  
60 
 
impaired. Due to this small sample size, a relatively high fold change cut-off value (±1.5) was 
had be to use in order to find the significant alterations between the test groups, whereas 
smaller alterations in the levels of detected metabolites could be considered as statistically 
significant if the sample size would be larger. Thus it would be highly necessary to increase 
the sample size in further studies in order to improve the statistical power. 
Our experimental data from LC-qTOF-MS analysis gave excess of peaks with bad quality or 
poor fragmentation of molecular ions. As an example of this are six statistically significant 
metabolites which were able to be tentatively identified, but not be considered as reliable 
markers due to their poor elution profiles or MS/MS fragmentations. In addition, there were 
several metabolites in the data, which could not be identified because their poor and too 
splintered MS/MS fragmentation spectrums. The reason underlying this technical problem 
may be in the extraction conditions, since a poor elution profile indicates challenges in the 
separation of different molecules in the sample during the extraction. Thus, it would be highly 
necessary to perform a few LC-MS experiments only in order to optimize the experimental 
conditions to improve the quality of the data, which is essential for reliable metabolite 
identification. This was a problem especially for lipids, since their peaks and elution profiles 
were poor indicating that several distinct lipids were co-eluting comprising huge peak clusters 
instead of high and well-defined single peaks. It can also be speculated if there is a room for 
improvement in taking the blood samples from dogs, since the quality of the whole blood 
samples used in this experiment was highly heterogeneous. Since it is well known that the 
sampling may have an effect to the results, the homogeneous quality of all the samples would 
be highly necessary. Also numerous other factors, such as the sampling time 
(morning/evening), dog’s physical activity and especially dog’s diet may have tremendous 
effects on the metabolite profiles detected, and thus all these factors should be taken into 
account when designing and performing metabolomics studies in the future. On the other 
hand, given the heterogeneous background of the pilot samples used in this study, the 
observed significant differences in some of the molecules could have been even more 
pronounced with more careful timing and preparation of the samples. 
In conclusion, the present study demonstrates the usefulness of non-targeted metabolomics 
approach to discover biomarkers for canine anxiety, although the experimental conditions of 
the LC-qTOF-MS analysis need to be optimized for further studies to improve the quality of 
the data. Also the sample material should be plasma or serum instead of the whole blood used 
in this study. To our knowledge, this is the first study utilizing an untargeted metabolite 
profiling in order to investigate the biological backgrounds of anxiety-related conditions in 
  
61 
 
dogs. These results suggest that the metabolite profile of an anxious dog differs from that of a 
non-anxious dog, and that disturbed lipid metabolism, and oxidative stress and inflammation, 
which further can cause crucial alterations in tryptophan metabolism, may be factors 
explaining this difference. Although there is no doubt that further studies are needed to define 
the reliability of these findings as a markers of canine anxiety, our results suggest that a non-
targeted metabolomics approach is an important and effective, although yet less used, 
technique also in dogs. Still, there is a huge demand for further investigations of the 
connections observed in this study, as well as for broader metabolomics study of anxious 
dogs. We hope that these findings will improve our understanding of the biological 
backgrounds of canine anxiety, and will inspire further studies investigating the molecular 
mechanisms and networks underlying the pathogenesis of anxiety-related disorders. 
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